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ABSTRACT
Drugs are potentially toxic substances that elicit dosage-dependent therapeutic effects
for specific disease conditions . The efficacy of a drug regimen depends on the
concentration of the drug at the site of needed activity and the duration of time it is
maintained . The selection of dosing regimens for different species requires the
establishment of pharmacokinetic equivalency between species; that is, achieving
equivalent peak serum and tissue concentrations and duration of drug exposure. Drug
metabolism is a direct reflection of the multiple enzyme systems that characterize
different species and is often the most important single factor in regulation if drug
concentrations in the body. The largest concentration of enzymes catalyzing these
reactions is located in the liver; however, significant concentrations also exist in other
tissues such as the intestine. The cytochrome P450 system metabolizes the majority of
drugs. Although cytochrome P450 enzymes exist in all species examined to date, minor
changes in the structure or tissue distribution of the enzymes may lead to great
differences in the metabolism and elimination of specific drugs. A lack of consideration
of the rates of biotransformation and elimination of drugs in animals particularly those
intended for food may result in drug residues , such as quinolones, in consumed meats.
Alternatively, ineffective drug concentrations may prevent killing of bacteria , leading to
contamination of meats. More important, low level antibiotic concentrations may favor
development of resistant bacterial strains. In an effort to determine pharmacokinetic
differences that can indirectly affect development of quinolone resistance in bacteria ,
differences in quinolone disposition will be identified by allometric analysis of
pharmacokinetic data from different species will be analyzed . Activities of specific
cytochrome P450 enzymes will be examined in swine.
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Chapter 1: Introduction
Designing Dosage Regimens
Drugs are potentially toxic substances that elicit dosage-dependent therapeutic
effects for specific diseases. A drug is usually described by its most prominent effect or
by the action thought to be the basis of the effect. However, such descriptions should
not obscure the fact that most drugs produce multiple effects. A drug is characterized
adequately only when its full spectrum of effects has been determined . The relationship
between the dosages of a drug associated with undesirable as well as desirable effects
is termed its therapeutic index, margin of safety, or selectivity. For therapeutic
applications, selective action of a drug is clearly one of its more important characteristics
(Nies and Spielberg , 1996). Furthermore , a drug may have more than a single
therapeutic index, if different indications require varied dosages.
It is typical to administer multiple doses of a therapeutic agent at intervals
appropriate for the drug preparation selected . The objective of the dosage regimen for
most drugs is to maintain plasma concentrations of the drug or its active metabolites
within the therapeutic range for the duration of treatment. Elucidation of the therapeutic
(safe and effective) range of plasma concentrations for a drug relies on determination of
concentration-response relationships for each therapeutic indication. Clinical evaluation
is required, with precise physiologic and biochemical characterization of the response in
a sufficient number of appropriately selected individuals. The effective concentrations
and width of the therapeutic range are considered to reflect inherent activity and relative
safety of a drug.
For some drugs, the pharmacologic effects are difficult to measure, toxicity and
lack of efficacy are potential dangers, and/or the therapeutic index is narrow.

In these

circumstances , dosage regimens must be titrated carefully and a target-level strategy
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applied. The desired plasma concentration of the drug is chosen that is expected to
achieve effective tissue levels while remaining within the therapeutic range, and a
dosage is computed that is expected to achieve this value. Monitoring of drug
concentrations in blood is indicated when possible, for drugs that have narrow
therapeutic indices. Although individual variation in response is usually present, the goal
of treatment is to achieve the established therapeutic range for a drug in order to avoid
ineffective treatment or toxicity.
Because patients differ in their response to drugs, treatment must be considered
unique to that individual. Individualization of therapy for a particular patient requires a
basic understanding of pharmacokinetics and pharmacodynamic s. The success of a
drug regimen depends on the achievement of effective concentration of the drug at the
site of needed activity. How long the drug effect can be maintained influences the
frequency of dosing, which impacts patient compliance. The pharmacokinetic
disposition of a drug depends on the anatomy and physiology of the patient as well as
specific properties of the drug itself. Factors that determine the relationship between
prescribed drug usage and drug effect can be divided into three categories : those that
affect the administered dose, those that affect the concentration at the site of action, and
those that intensify the effect (Poklis, 1996).
Factors that affect the administered dose are: rate and extent of absorption, body
size and composition , distribution in body fluids, binding to plasma proteins and tissues,
and rate of elimination . Those that affect the concentration at the site of action are
interaction with other drugs, development of tolerance, genetic factors, pathological
factors, and physiological variables such as pH and pKa of drug. Factors that can
intensify the effect are drug-receptor interaction, physiological state of the patient, and
placebo effects. In order to design an appropriate therapeutic dosage regimen, all
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sources of variation in response to the drug must be considered. Without consideration
of these factors, therapy may be ineffective or produce deleterious effects. For example,
inappropriate dosages of antibiotics such as quinolones used in animals intended for
food may indirectly harm the consumer by favoring development of antibiotic-resistant
bacteria, or through inadvertent consumption of drug residues .
Extrapolating Dosages Between Species using Allometry
The extrapolation of dosing regimens between species requires the
establishment of pharmacokinetic equivalency; that is, achieving equivalent peak serum
and tissue concentrations and duration of drug exposure (Frazier et al., 1995). The
ability to achieve equivalency relates to the physiologic and morphologic characteristics
of the tissues and organs responsible for drug absorption, distribution, metabolism and
excretion . The appropriateness of drug dosage extrapolation between species depends
on the similarity of the pharmacokinetic behavior of the drug for the species.
The allometric approach is a basic mathematical tool for analyzing differences in
anatomy, physiology, biochemistry, and pharmacokinetics in animals of different sizes .
At least 750 allometric equations have been reported (Calder, 1984). The usual
allometric approach relates one biologic function or structure (y) to another (x) through
an empirical power function:
y = a(xt
The extrapolation of pharmacokinetic parameters from one animal to another is
based on allometric expressions of relative body size. This means that a small animal
has a specific basal metabolic rate (kcal/kg) that is greater than that of a large animal
(when both are of a group having the same mean core body temperature range)
(Sedgwick, 1993). A smaller animal, with its higher metabolic rate , has a more rapid
mean circulation time, higher densities of capillaries per unit of any given tissue, more
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respiratory surface area for gas exchange, a higher glomerular filtration rate, greater
hepatic enzyme activity, and higher intracellular densities of mitochondria and
cytochrome C (important to tissue metabolism) per unit of body size than a larger animal
(Schmidt-Nielsen, 1984). In other words, small-size animals are expected to have more
metabolic activity per unit of body mass that may affect drug disposition than that of
large animals.
To illustrate the importance of considering differences in metabolic rate when
extrapolating treatment regimens , consider that a mouse is only 1/2800 the size of the
human, but its dose rate and treatment frequency of an antibiotic were both found to be
more than six-fold that of the human. If a clinician were to treat a mouse patient with the
human antibiotic regimen, the therapeutic serum level could never be reached, but if the
human patient were treated with the mouse regimen , it would surely prove toxic
(Sedgwick, 1993).
The perceptive clinician must consider the mechanisms of drug absorption,
biotransformation, distribution, and excretion to determine the appropriateness of
extrapolating dosages between species. Allometric equations reveal quantitative
differences, but not necessarily qualitative differences, in structure or function between
animals associated with differences in body weight. Qualitative differences (in structure
or function) can change the relationship to body weight and yield a different value for
either a orb. Use of an incorrect estimate for either a orb can grossly over-estimate or
under-estimate clearance of a drug (Frazier et al., 1995). Due to the development of
bacterial resistance to older more established antibiotics, newer drugs such as
quinolones are being used in a variety of species; however, not much is known about
the allometric relationships of these drugs.
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Effect of Drug Metabolism on Dosage Regimens
Although laboratory animals are considered to be adequate predictors of the
effects of drugs on other species, species-dependent differences in drug metabolism
often hinders extrapolation of efficacious, non-toxic dosages. For drug safety and
efficacy reasons, it is of paramount importance to determine metabolic pathways, and to
identify the active cytochrome P450 enzymes involved.
1. Mechanisms of Drug Biotransformation
Drug metabolism is a direct reflection of the multiple enzyme systems that
characterize different animal species, and it is often the most important single factor in
the regulation of plasma drug concentrations . Reactions catalyzed by these
biotransforming enzymes are generally divided into two groups called phase I and phase
II reactions. Phase I reactions involve oxidation, reduction , and hydrolysis. These
reactions introduce a functional group (-OH, -NH 2 , -SH, or -COOH) that increases water
solubility and excretion, or provides a "handle" which is used in the second phase
reactions. Phase II biotransformation reactions include glucuronidation , sulfation,
acetylation, methylation, conjugation with glutathione, and conjugation with amino acids.
Most phase II reactions result in a large increase in hydrophilicity of the compound;
hence, they greatly promote excretion.
In many instances, chemical modification by metabolism also alters the biological
effects of the compound. The importance of this principle is that some drugs must
undergo biotransformation in order to exert their pharmacodynamic effect (i.e., it is the
metabolite of the drug, and not the drug itself, that exerts the pharmacological effect)
(Parkinson, 1996). In most cases, however, biotransformation decreases or terminates
the pharmacological effects of a drug and lessens its toxicity.
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The largest concentration of enzymes catalyzing biotransformation reactions is
located in the liver. Significant concentrations of specific enzymes are also located in
the skin , lung, nasal mucosa, eye , gastrointestinal tract, kidneys , adrenal gland ,
pancreas , spleen, heart, brain, testis, ovary, placenta, plasma, erythrocytes, platelets,
lymphocytes, and aorta (Parkinson , 1996). The enzymes are located primarily in the
endoplasmic reticulum (microsomes), or the soluble fraction of the cytoplasm (cytosol),
with lesser amounts in the mitochrondria, nuclei, and lysosomes. Hepatic extraction and
biotransformation of compounds absorbed from the gastrointestinal tract limits the
systemic bioavailability of orally ingested compounds , a process known as first pass
elimination (Parkinson , 1996; Back and Rogers , 1987). In some cases ,
biotransformation in the intestine contributes significantly to first pass elimination of
compounds (Parkinson , 1996).
2. Cytochrome P450 Enzymes
Among the phase I biotransforming enzymes , the cytochrome P450 system
ranks first in terms of catalytic versatility and the sheer number of compounds it
detoxifies or activates to reactive intermediates (Parkinson , 1996; Guengerich , 1992).
The largest concentration of P450 enzymes is located in the liver endoplasmic reticulum
(microsomes) , but they are located in virtually all other tissues . These enzymes also
perform important roles in the activation of xenobiotics to toxic and/or tumorigenic
metabolites as well as being involved in the biosynthesis of steroid hormones, bile acids ,
fat-soluble vitamins , and fatty acids. P450 enzymes play a very important role in
determining the intensity and duration of action of drugs, and they also play a key role in
the detoxification of xenobiotics .
Cytochrome P450 enzymes are present in all species examined, including
bacteria , fungi , insects, plants, fish , amphibia , and mammals (Doehmer et al. , 1993). At
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least 221 different cytochrome P450 enzymes have been described (Nelson et al.,
1993). Protein and gene sequence alignments and comparisons have revealed
interrelationships between the different cytochrome P450 enzymes (Gotch, 1992). They
have been classified into 36 gene families of which 12 families exist in all mammals.
These 12 fam ilies comprise 22 mammalian subfamilies . About 70 different human
cytochrome P450 enzymes are known , and a uniform nomenclature has been developed
and recommended . In general, P450 enzymes with less than 40 percent amino acid
sequence identity are assigned to different gene families ( gene families 1,2,3,4 etc.)
P450 enzymes that are 40 to 55 percent identical are assigned to different subfamilies
(2A, 2B, 2C, etc.). The P450 enzymes that are more than 55 percent identical are
classified as members of the same subfamily (2A1, 2A2, 2A3, etc.) (Parkinson , 1996).
Hepatic microsomal P450 enzymes involved in xenobiotic biotransformation belong to
three main P450 gene families : CYP1 , CYP2 , and CYP3. Hepatic microsomes also
contain P450 enzymes encoded by the CYP4 gene family. The substrates for the latter
enzymes include several fatty acids and eicosanoids , but relatively few xenobiotics
(Parkinson, 1996). P450 enzymes in liver microsomes of these gene families generally
belong to a single subfamily (i.e., CYP1A, CYP3A, and CYP4A). The exception to the
single family rule is the CYP2 gene family which contains five subfamilies (i.e ., CYP2A,
2B , 2C, 2D, and 2E) (Parkinson , 1996). The number of P450 enzymes in a subfamily
differs between species (Parkinson, 1996).
Recent studies have been directed at molecular mechanisms underlying the
broad but specific metabolic capacities of P450 enzymes. These enzymes comprise a
relatively limited number of catalysts that have partial overlap but distinct substrate
specificities . There have been various experimental and analytical investigations
involved in the determination of recognition or binding of substrates and substrate
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specificity. These include site-directed mutagenesis, chemical modifications with
substrate analogues, and sequence alignment (Gotoh, 1992; Guengerich , 1994 ).
Sequence alignment has become much more feasible in the last several years due to
the availability of commercial software. A large number of mammalian sequences are
now accessible from databases such as GenBank, SwissProt and GenEMBL.
Sequences for CYP1A1 and 1A2 have been reported for the following species : rat,
human, rabbit, dog, hamster, monkey, guinea pig, mouse, trout, and chicken (Nelson et
al. , 1993). Sequences for the 3A family have been reported for: sheep, human, rat,
rabbit, monkey, hamster, and dog (Nelson et al. ,1993). 2E1 sequences have been
reported for: human , rat, rabbit, monkey and mouse, while the 20 family has been found
in : human , dog , mouse, and cow, rat and pig (Nelson et al. , 1993).
A number of highly conserved sequences throughout the P450 family have been
discovered using this alignment process . The alignment process has also revealed
areas with excessively high non-synonymous amino acid substitutions, which coincide
with potential substrate binding sites (Gotoh , 1992). These are called substrate
recognition sites (SRS's). There are six of these proposed SRS sites that make up
roughly 16% of a total sequence (Gotoh , 1992). Many site directed mutations that affect
metabolism fall within these SRS's (Gotoh , 1992; Ellis et al. , 1995). Certain amino acids
or sequences are known to be well conserved across species (Lewis and Moereels,
1992; Edwards et al. , 1989; Johnson et al. , 1992; Yamazaki et al. , 1993), while others in
the P450 families vary (Gotoh , 1992; Ellis et al. , 1995; Johnson et al. , 1992; Negishi et
al. , 1996; Krainev et al. , 1992). The emphasis to date has been on determining
sequence homologies of cytochrome P450's (Lewis and Moereels, 1992; Edwards et al. ,
1989; Sakuma et al. , 1994; Komori et al. , 1992), with very few comparisons of the
relationship between variability in sequences and xenobiotic biotransformation .
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3. Species Differences in Metabolism
Variations in rates of drug metabolism have been recognized in humans (Nies
and Spielberg, 1996; Poklis, 1996; Guengerich , 1992) and other species (Nies and
Spielberg, 1996; Poklis, 1996; Smith, 1991; Mellett, 1969). The effect of genetic
polymorphism in cytochrome P450 metabolizing enzymes can lead to dramatic changes
in therapeutic concentrations at the site of action. When different individuals are
administered identical dosages of a drug at similar time intervals, it is not uncommon to
observe large differences in plasma concentrations of the drug. The classic example is
the polymorphism described for CYP2D6 . Two distinct classes of fast (those that never
attain therapeutic plasma concentrations) and slow (those that attain excessive plasma
concentrations) metabolizers have been observed among the human population. They
are characterized by their efficiency in the metabolism of either debrisoquine or
sparteine (Coutts, 1994; Gaedigk et al., 1991 ). CYP2D6 is also responsible for the
metabolism of antidepressants, cardiovascular agents, morphine derivatives,
psychoactive drugs and anticonvulsants (Doehmer et al. , 1993; Coutts, 1994; Gaedigk
et al., 1991 ). Results of studies indicate that slow (or poor) metabolizers have a total
absence of the hepatic CYP2D6 protein (Gaedigk et al., 1991 , Brosen, 1990). It is
prudent to recognize that genetic factors can lead to significant variations in a
therapeutic response to, and side-effects of, a particular drug. Although not routinely
done, phenotyping of the patient prior to administration of a drug may aid in determining
the proper therapeutic dose.
One of the main differences between humans and lower animals is the rate of the
reactions which transform drugs (Smith, 1991 ). There are important species differences
in the function and regulation of the cytochrome P450 enzymes. Variations have been
attributed in part to the presence of different P450 enzymes, and to their inducibility
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(Guengerich, 1992). Differences also occur in the response of cytochrome P450
enzymes between species (Smith, 1991; Boobis et al., 1990). Possible reasons for
species differences are: the relative concentrations of different biotransforming
enzymes, the active site of the enzyme differs among species, activity is catalyzed by
different enzymes or isozymes (the enzyme may be in one species but completely
missing in another), differences in the specificity of the isozyme, and differences in the
pathways competing for the substrate (Parkinson, 1996; Mellett, 1969; Boobis et al.,
1990). Any one or combination of these reasons can have a tremendous impact on the
way a compound is metabolized by a particular species. A compound that is effectively
used in one species could be useless because it is not metabolized in another, while a
therapeutic dose in one species could prove to be lethal in another due to differences in
metabolism.
Although food safety is of increasing concern to the public, little has been done
to characterize specific P450 isozymes in food animals (Broad et al., 1995). Quinolones
represent a class of antibiotics about which limited information on P450 enzyme
metabolism is available in domestic animals. Because the use of these drugs is likely to
increase in food animals, further information about the rates of metabolism to active and
inactive metabolites is needed.
4. Distinguishing Between Parent Compound and Metabolite
The structural diversity of the multitude of modern therapeutic drugs is well
documented (Nies and Spielberg, 1996; Poklis, 1996). To date, most pharmacokinetic
drug studies have focused only on identification of parent compounds. Because the
efficacy and toxicity of the administered drug may depend on one or more metabolites
as well as the parent compound, the isolation and structural characterization of the
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resulting array of metabolites is vitally important to understanding the physical and
biological effects of the parent drug.
Isolation of drug metabolites from biological material is often difficult due to low
concentrations in urine, bile or blood, and high concentrations of interfering endogenous
compounds and food constituents (Dieterle and Faigle, 1983). The physico-chemical
properties of the more polar metabolites, notably conjugates, further complicates their
isolation in pure form (Dieterle and Faigle, 1983). Some metabolites may require
chemical modification or thermal degradation in order to affect a separation .
Furthermore, phase I metabolism of a drug often results in only minor structural
modification of the parent compound, and determination of suitable chromatographic
conditions to produce a separation of mixtures of drug metabolites is often particularly
difficult (Naylor et al., 1996).
Quinolones consist of a bicyclic ring structure in which there is a substitution at
position N-1, with various moieties. All of the current agents have a carboxyl group at
position 3, a keto group at position 4, a fluorine atom at position 6, and a piperazinyl
group or a methylpiperazinyl group at C-7. Differences in the moiety present at the N-1
and C-7 positions markedly influence both microbiological and pharmacokinetic
properties. The extent to which different quinolones undergo hepatic biotransformation
varies . Although glucuronide conjugates have been identified as minor metabolites,
most metabolic reactions involving quinolones occur through microsomal oxidative
mechanisms at the cytochrome P450 site.
Ciprofloxacin belongs to the potent antimicrobial group termed fluoroquinolones ,
and chemically is defined as 1-cyclopropyl-6-fluoro-1,4-dihyrdo 4-oxo-7-( 1-piperazinyl)3-quinolone carboxylic acid. Ciprofloxacin undergoes biotransformation in the liver to
four metabolites: desethylene-ciprofloxacin (M-1 ), sulfo-ciprofloxacin (M-2), oxo-

13
ciprofloxacin (M-3) and formyl-ciprofloxacin (M-4 ). These metabolites are formed by
piperazine-ring cleavage, sulfa-conjugation, piperazine-ring oxidation and N-formyl
conjugation. Ultimately these metabolites are excreted in both bile and urine of humans.
However, very limited information is available with regard to metabolites that are formed
in food animals. The M1 and M3 metabolites are products of cytochrome P450
metabolism. Sulfo-ciprofloxacin (M2) is produced by a reaction that is catalyzed by
sulfotransferases, soluble enzymes that are found primarily in the liver and intestinal
tract (Parkinson , 1996). Sulfation can occur with or without prior biotransformation by
phase I enzymes, and most of the sulfated conjugates are excreted in the urine. Swine
are deficient in this class of enzymes while chickens are not. Little is known about the
formyl metabolite; however, it accounts for less than 1% of the metabolites recovered
after oral administration of ciprofloxacin in humans (Outman and Nightingale, 1989).
Designing Dosage Regimens to Prevent Development of Bacterial Resistance
Pharmacodynamics is concerned with the relationship between concentration
and the pharmacologic and toxicologic effects of drugs. The primary focus for
antimicrobial agents is the relationship between drug concentration and the antimicrobial
effect. The efficacy of these agents is increasingly being compromised by the
development of bacterial resistance. It is clear that resistance to any class of
antimicrobial agent increases as the level of use increases due to selective pressure
(Smith and Lewin, 1993). Furthermore, the arbitrary use of antimicrobial agents
exacerbates the development of resistance when used at insufficiently high dosages, for
inappropriate durations of therapy, or for use in clinically ill patients who do not warrant
such treatment. Both the human and veterinary medical professions must be made
aware of the need to prescribe and/or administer antimicrobial agents more
conscientiously in order to minimize the development of resistance.
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The four mechanisms of antibiotic resistance are: inactivation or destruction of
the drug, altered permeability of the bacterial cell wall or membrane, active expulsion of
the drug by the cell efflux pump and altered target site (i .e., the ribosome) resulting in
decreased susceptibility to the antibacterial agent (Smith and Lewin, 1993; Rasmussen
et al., 1997; Prescott, 2000). These drug resistance determinants are mediated via one
of two distinct genetic mechanisms; a mutation in the bacterial chromosome or by
transferable elements (Smith and Lewin, 1993). Transferable drug resistance can occur
by transduction, transformation, conjugation, transposons, and integrons (Prescott,
2000). Significant differences exist between these two types of drug resistance
mechanisms. Transferable antibacterial resistance permits intraspecies and interspecies
transfer to occur, and can lead to the rapid development of antibacterial resistance .
Transferable resistance has proven difficult, if not impossible, to eradicate. In contrast,
chromosomal resistance usually is only passed on to progeny and is a gradual stepwise
process.
The fluoroquinolones are a series of synthetic antibacterial agents used in both
human and veterinary medicine. They are rapidly bactericidal with a spectrum of activity
against gram-negative bacteria, mycoplasma, and some gram-positive bacteria. They
work through the inhibition of DNA gyrase, interfering with the supercoiling of bacterial
chromosomal material. Mechanisms of resistance for quinolones have been
characterized for several bacterial species. Three principal mechanisms have been
described : decreased permeability of the bacterial cell wall caused by alterations of the
hydrophilic pores; an efflux pump, which actively transports the fluoroquinolone molecule
out of the cell as it approaches or passes through the bacterial membrane; and mutation
of the DNA gyrase or topoisomerase IV, thus altering the binding site of quinolones
(Prescott, 2000). Plasmid-mediated resistance has been described but not confirmed

15
(Cambau and Gutmann, 1993). Development of resistance is the greatest source of
debate for the use of quinolones in animals. Because quinolones are the drugs of
choice for many refractory and/or nosocomial infections in humans , regulatory pressure
has restricted their use in animals in order to minimize the development of resistance.
Federal law now restricts the usage of quinolones in food producing animals,
even though the agricultural community insists that quinolone usage in food animals is
necessary to prevent production losses and bacterial contamination of meat. These
restrictions have resulted from concerns from the health care community and the general
public regarding the increasing development of drug resistant bacterial strains, and
because of the problems this could pose to human and animal health.
The hypothesis of this study was that species-dependent differences in
pharmacokinetic disposition of quinolones are due to differences in distribution or activity
of cytochrome P450 isozymes. Differences in pharmacokinetic parameters can
indirectly affect development of quinolone resistance by bacteria . The specific aims of
the study were to : 1) Identify differences in quinolone disposition by allometric analysis
of pharmacokinetic data of different species, and 2) identification of species-dependent
metabolism pathways. This involves identifying differences in P450 metabolism in
hepatic tissue of swine using specific substrates and inhibitors. Part two of the study
also required the development of specific techniques in order to identify P450
differences.
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PART 11: ALLOMETRIC ANALYSIS OF CIPROFLOXACIN AND ENROFLOXACIN
PHARMACOKINETICS ACROSS SPECIES
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Chapter 1: Abstract
The purpose of this study was to examine the allometric analysis of ciprofloxacin
and enrofloxacin using pharmacokinetic data from the literature. The pharmacokinetic
parameters used were half-life, clearance and volumes of distribution. Relationships
between body weight and the pharmacokinetic parameter were based on the empirical
formula Y=aWb where Y is half-life, clearance or volume of distribution; W is body
weight; and a is an allometric coefficient (intercept) that is constant for a given drug.
The exponential term b is a proportionality constant that describes the relationship
between the pharmacokinetic parameter of interest and body weight. A total of 20
different species of animals were studied . Results of the allometric analyses indicated
similarity between clearance and volume of distribution as they related to body weight
for both drugs. Absence of significant relationships for half-life may be due to
differences in the rate or extent of drug biotransformation. Results indicate that it is
possible to use allometry to predict some pharmacokinetic variables of enrofloxacin or
ciprofloxacin based on body size of species.
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Chapter 2: Introduction
Drug dosage extrapolation among species assumes that pharmacodynamic
similarities exist when pharmacokinetic equivalency is achieved . In other words,
achieving equivalent peak serum and tissue concentrations and duration of drug
exposure will achieve similar physiologic effects among species. Species-dependent
differences at the site of drug action , such as the number of receptors or affinity of
receptors for the drug, can preclude achieving equivalent effects for many classes of
drugs. But achieving equivalent antimicrobial drug exposure in different species should
achieve similar killing of microorganisms. The ability to achieve pharmacokinetic
equivalency depends on the physiology and morphology of the tissues and organs
responsible for drug absorption, distribution, biotransformation, and excretion of drugs .
The allometric approach is a basic mathematical tool for analyzing differences in
anatomy, physiology, biochemistry, and pharmacokinetics in animals of different sizes.
At least 750 allometric equations have been reported (Calder, 1984). The usual
allometric approach relates one biologic function or structure (y) to another (x) through
an empirical power function:

y = a(xt
Drug effect is often related to pharmacokinetic parameters of a drug, including
half-life (t½), clearance (Cl), volume of distribution (Vd), or the area under the drug
concentration versus time curve (AUC) (Baggot 1977; Rowland 1986; Benet et al.,
1996). Because most pharmacokinetic parameters are dependent on physiologic
functions, it is possible to consider drug dosages among species on the basis of
allometric relationships; i.e., where y is the value of the pharmacokinetic parameter and
xis body weight (Boxenbaum 1982; Riond and Riviere 1990; Pashov et al., 1997;
Riviere et al., 1997). Allometry may be performed on any pharmacokinetic parameter;
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however, the half-life profile, with abundant data in the literature is most often studied .
Half-life is a composite of Vd and Cl. Therefore, Cl can be studied and may provide less
biased information .
Interspecies scaling assumes that biochemical and physiologic processes
responsible for rate of drug elimination vary in accordance to basal metabolic rate . A
number of physiologic factors other than basal metabolism can modify these
biochemical/physiological relationships and cause variations in half-life, volume of
distribution and clearance of drugs that are unrelated to body mass . These factors
include change in protein binding , saturation of drug elimination processes, diet, genetic
polymorphism, drug-induced alterations in physiologic processes, biotransformation ,
interspecies differences in enterohepatic circulation , and tubular reabsorption as
influenced by urinary pH (Mellett 1969; Williams 1973; Sergei 1989; Riviere et al., 1997;
Pashov et al. , 1997). Differences in pharmacokinetic parameters and biologic activity of
drugs among species may be related to physicochemical interactions of drugs with food ,
or to biodegradation of compounds in the rumen , caecum , or colon (Baggot 1977, 1980,
1990; Pashov et al., 1997).
Fluoroquinolones, such as enrofloxacin and ciprofloxacin , have similar
distribution characteristics ; however, elimination pathways and rates differ considerably
among species. Oral absorption of fluoroquinolones is generally fast and substantial in
humans, monogastric species, and pre-ruminant age calves, with up to 80% of the
ingested dose absorbed into the systemic circulation (Vancutsem et al., 1990). These
drugs have volumes of distribution greater than 1 I/kg. Binding to plasma proteins is
va ri able among species (Bregante et al. , 1999) and for the different quinolones (Zlotos
et al. , 1998a; Zlotos et al., 1998b). Major elimination pathways are renal excretion and
hepatic metabolism . In the kidneys, fluoroquinolones are affected by glomerular
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filtration , tubular secretion, and tubular reabsorption . In the liver, they are metabolized
primarily by oxidation but also demethylation and deethylation of the parent molecule
(Lode et al. , 1989). Conjugative pathways are predominant for some fluoroquinolones in
most species (Sergei 1989); however, the degree of metabolism varies considerably
across species.
Pharmacokinetic characteristics of ciprofloxacin and enrofloxacin,
fluoroquinolones that inhibit DNA gyrase in bacterial cells , have been determined in
several different species. The objectives of this study were to determine relationsh ips
between body weight, half-life, clearance and volume of distribution for these two
fluoroquinolones that may impact interspecies scaling of drug doses. In particular,
whether allometric scaling based on body weight could be used to predict these
pharmacokinetic variables .
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Chapter 3: Materials and Methods
The relationships between body mass and elimination half-life (t½), volume of
distribution at steady state (Vdss), or total body clearance (Cl) of ciprofloxacin and
enrofloxacin were analyzed using data from studies in 20 species: 13 for ciprofloxacin
(Table 2-1) and 14 for enrofloxacin (Table 2-2). Data fort½, Vdss, and Cl of both drugs
was obtained from previously published studies. Half-life values were determined during
the elimination phases after intravenous (i.v.) administration of the drugs. The matrices
of interest were serum, plasma, or blood. Data for body weights were obtained from
these same studies. Mean values were used when a range of body weights was given.
When body weights were not indicated, average values for the species and breed used
in this study were obtained from the literature. Records were deleted if subjects were
diseased or other drugs were co-administered . Analyses did not consider the influence
of age or sex. Regression analyses were preformed on data from studies where HPLC
analyses were done for both enrofloxacin and ciprofloxacin . Biological methods
(microbiologic assay) do not differentiate between parent compounds and active
metabolites of enrofloxacin and ciprofloxacin and were not included.
Data were separated into 2 groups for both drugs. The groups were: 1) all
species (including mammals, fish, reptiles, and birds), and 2) mammals only.
Regression analysis of values for body weight, t½, Cl or Vdss was performed
using SAS software (SAS Institute, Cary, NC, USA). The analyses were performed
using mean values from individual citations. The linear regression of log half-life (t½,
hr), log volume of distribution (Vdss, I/kg) or log clearance (Cl, ml/min/kg) versus log
body weight (W, kg) was analyzed so that estimates of the intercept c and slope b could
be computed by the following equations:
log t½ = c + b(log W), log Vdss = c + b(log W) or log Cl = c + b(log W)
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TABLE 2-1 . Ciprofloxacin animal species database.
Species
t½ {hr)
Cl
(ml/min/kg}
Bos domesticus
2.4
12.1
Cow

Vdss (I/kg)

Source
Nouws et al. , 1988a

Sus scrota
Pig

2.6

17.3

Ovis ovis
Sheep

1.2

18

*

Munoz et al , 1996

Orictolagus uniculus
Rabbit

1.6

27 .2

*

Aramayona et al., 1996

3, 2.2, 2.6
2.8

19, 18, 14
7.8

*
1.9

Abadia et al., 1994
Cester & Toutain 1997

Rattus rattus
Rat

2.2
1.7

26.7
33

4.6
9.2

Siefert et al. , 1989
Nouaille et al. , 1998

Macaca mulatta
Monkey

4.3

4.7

1.8

Siefert et al. , 1989

4.3, 4.4
2.7, 2.9, 2.8
2.9
4.2
2.3
3.6, 3.7, 3.5
3.7
3.6, 3.7, 3.5,
3.4, 4, 3.6
4.2
3.3, 3.7, 3.5
4.8, 3.3
2.7

8.3, 8.2
9.6, 9.6 , 8.2
9.3
8.2
9.8
8.8 , 7.6, 7.8
9.6
9.2, 8, 8.7,
8.7, 8.7, 8.3
8.7
8.1, 7.9, 7
10.6, 10.2
19.6

2.4, 2.4
9.6, 9.6, 8.2
*
2
*
2.1, 1.9, 1.8
2.0
***
***
2.3
2.2, 2.3, 1.9
* *
'
3.4

Gallus gal/us domesticus
Chicken

2.3
3.1

12.5
15.5

1.8
4.0

Garcia Ovando et al.
1997
Garcia Ovando et al.,
1999

Cyprinus carpio
Carp

14.5

2.5

2.7

Nouws et al. , 1988b

Sa/mo gairdneri
Trout

11.2

4.8

2.7

Nouws et al. , 1988b

Canis famillaris
Dog

Homo sapiens
Human

Capra hircus
Goat

Nouws et al. , 1988a

Lettieri et al., 1992
Dudley et al., 1987a
Bergan et al. , 1987
Dudley et al. , 1987b
Deppermann et al. , 1989
Nix et al. , 1992
Wingender et al., 1984
Bergan et al. , 1988
Catchpole et al., 1994
Ljungberg et al., 1988
Lode et al., 1988
Garcia Ovando et al.,
2000

Clarias gariepinus
14.2
5.6
Nouws et al. , 1988b
4.5
African catfish
* Missing data. When more than one value is listed , they represent multiple doses in the article.
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TABLE 2-2. Enrofloxacin animal seecies database.
Cl
t½ (hr)
Species
(ml/min/kg}
3.2, 6.5
6.6, 4.9
Bos domesticus
7.5
16.3
Cow

Vdss
(I/kg}
1.8, 2.3
*

Source
Kaartinen et al., 1997a
Martinez-Larranaga et al. ,1997

Sus scrofa
Pig

7.3
7.7
3.5
9.6
21

6.2
4.5
7
1.7
2.7

3.9
2.7
*
1.3
5.5

Nielsen & Gyrd-Hansen 1997
Richez et al. , 1997b
Zeng & Fung 1997
Anadon et al., 1999
Post et al., 2002

Ovis ovis
Sheep

3.7
3.8

9.2
4

3.0
*

Mengozzietal., 1996
Pozzin et al., 1997

Orictolagus uniculus
Rabbit

2.2
1.9

22.8
23.9

3.4
*

Cabanes et al. , 1992
Aramayona et al. , 1996

Canis famillaris
Dog

2.4
4.4
2.3

27.1
10.9
12.2

7
3.7
2.5

Kung etal., 1993
Monlouis et al. , 1997
Cester & Toutain 1997

Lama glama
Llama

3.4

11 .7

3.5

Christensen et al. , 1996

Fe/is domestica
Cat

6.7

9.5

4

Richez et al., 1997a

11.9, 5.8,
4.9, 5.8,
3.8

1.0, 1.4,
1.2, 1.4,
1.4

* * * * *

Harron et al., 1997

Equus cabal/us
Horse

17.1
4.4

1.7
8.5

2.5
2.3

Bermingham et al., 2000
Kaartinen et al., 1997b

Capra hircus
Goat

1.1
4.0

13.5
4

1.2
1.2

Rao et al. , 2000
Elmas et al., 2000

Gallus gal/us domesticus
Chicken

10.3
7.5
6.5
7.0
5.6

4.8
3
*
3.3
10.3

2.8
1.8
*
2.0
3.9

Anadon et al. , 1995
Garcia Ovando et al. , 1997
Kietzmann et al., 1997
Garcia Ovando et al. , 1999
Knoll et al. , 1999

Dormaius novaehollandiae
Emu

3.3

6

1.6

Helmick et al., 1997

Chlamydotis undulata
macqueenii
Houbara bustard

5.6

5.7

3.0

Bailey et al., 1998

Came/us dromedarius
Camel

Martinsen & Horsberg 1995
6.1
2.3
34.2
Sa/mo salar
Atlantic salmon
* Missing data . When more than one value is listed, they represent multiple doses in the article.
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The allometric equation was then applied (t½

=a(Wt , Vdss =a(W)b or Cl =a(Wt),

where a is the antilogarithm of c. Coefficients of determination and P-values were
computed for each regression analysis under study. Double logarithmic plots of body
weight vs . half-life, clearance or volume of distribution were constructed to demonstrate
significance found in the regression analyses.
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Chapter 4: Results
Results of the regression analyses conducted on the logarithm of half-life,
volume of distribution or clearance versus the logarithm of body weight for ciproftoxacin
are listed in Table 2-3. There was a statistically significant relationship between
clearance (p

=0.0001) and volume of distribution (p =0.0001) compared to body weight

when all species were analyzed, while there was an absence of relationship between
half-life and body weight. Ciprofloxacin half-life (Figure 2-1 ), clearance (Figure 2-2) and
volume of distribution (Figure 2-3) were related to body weight in mammals, with pvalues of 0.002, 0.0001 and 0.0001, respectively.

TABLE 2-3. Ciprofloxacin half-life, clearance and volume of distribution values for
allometric eguations.
P-value
?
b
A
n
Groue
Half-life
0.060 NS
-0.073
4.2
0.088
40
All Species
0.249
0.102
0.002
2.1
Mammals
35

All Species
Mammals

40
35

Clearance
5.8
20.7

All Species
Mammals

23*
18*

Volume of Distribution
2.0
3.1

1.12
0.816

0.914
0.905

0.0001
0.0001

1.09
0.979

0.948
0.870

0.0001
0.0001

n sample size; a allometric coefficient; b allometric exponent; ? = coefficient of
determination; NS = not significant; *reference lacked data resulting in different n values
between clearance, half-life and volume of distribution data
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The results of the regression analyses conducted for enrofloxacin half-life,
volume of distribution and clearance are listed in Table 2-4. The enrofloxacin allometric
analysis was similar to that of ciprofloxacin . There was a lack of association for half-lives
and body weights among all species for enrofloxacin. Clearance (p = 0.0001) and
volume of distribution (p = 0.0001) were significantly related to body weight in the
analysis. Enrofloxacin half-life (Figure 2-4) was not significantly associated with body
weight when mammals were analyzed. However, the analysis of volume of distribution
(Figure 2-5) or clearance (Figure 2-6) and body weight in mammals produced a
significant relationship (p = 0.0001).

TABLE 2-4. Enrofloxacin half-life, clearance and volume of distribution values for
allometric e9uations.
P-value
b
A
n
GrouQ
Half-life
0.0167
-0.043
0.468 NS
6.6
34
All Species
0.168 NS
0.0777
0.120
3.4
Mammals
26

?

All Species
Mammals

33*
26

Clearance
8.8
28.7

0.818
0.541

0.782
0.545

0.0001
0.0001

All Species
Mammals

24*
17*

Volume of Distribution
3.4
4.0

0.909
0.886

0.927
0.839

0.0001
0.0001

=

=

=

=

n sample size; a allometric coefficient; b allometric exponent; ? coefficient of
determination; NS = not significant; *reference lacked data resulting in different n values
between clearance, half-life and volume of distribution data
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Chapter 5: Discussion
In studies (Boxenbaum, 1982; Riviere et al. , 1997; Bregante et al., 1999) where
there has been an allometric relationship for half-life values for the allometric exponent
(b in our study) have ranged from 0.2 to 0.3. We found that our allometric exponent is
0.1 or less for both ciprofloxacin and enrofloxacin .
The lack of statistically significant relationships between both ciprofloxacin and
enrofloxacin half-lives may be due to considerable variation in biotransformation that
exists among species . Ciprofloxacin is metabolized to desethylene-ciprofloxacin (M 1),
sulfo-ciprofloxacin (M2), oxo-ciprofloxacin (M3) and formyl-ciprofloxacin (M4) in humans
as well as dogs, rats , mice, and monkeys (Outman and Nightingale 1989; Sorgel 1989).
There have been trace amounts of ciprofloxacin metabolites detected in calves and pigs
(Nouws et al., 1988a); however, the extent of metabolism varies. Enrofloxacin is N
deethylated to form ciprofloxacin; however, the rate and extent of this conversion varies
among species. For instance, the extent of ciprofloxacin formation was 22% in dogs,
(Monlouis et al. , 1997) 10% in cats, (Richez et al., 1997a) 29% in goats, (Rao et al. ,
2000) 35% in sheep, (Mengozzi et al., 1996) 10% in chickens, (Garcia-Ovando 1999)
20-35% in horses, (Kaartinen et al. , 1997b) and 35% in cows (Kaartinen et al., 1995). In
pigs and foals , there were only trace amounts of ciprofloxacin metabolized from
enrofloxacin (Zeng & Fung 1997; Bermingham et al. , 2000; Nielson & Gyrd-Hansen
1997).
Species variation in drug half-life exists for many drugs that are eliminated mainly
by hepatic metabolism . In mammalian species, the rates of phase I metabolic reactions
are variable. There is less certainty associated with hepatic conjugation reactions
because some are either defective or absent in certain species. As stated by Brodie
"the differences in drug-metabolizing enzymes among species are so variable that,
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similarities between animals and humans are often a matter of pure luck" (Brodie 1964 ).
For example, cats are deficient in some glucuronidation reactions due to a lack of
UDPglucuronyltransferase (Dutton et al., 1977; Dutton 1980). In this study, cats
exhibited a longer half-life than dogs, goats, llamas, emus or camels.
In our study, total body clearance was associated with body weight with
allometric exponents of 0.8 (all species) and 0.5 (mammals) for enrofloxacin, while
ciprofloxacin exponents were 1.1 and 0.8 for all species and mammals. In other reports
(Boxenbaum, 1982; Bregante et al. , 1999), the exponents ranged from 0.60 to 0.82. The
0.8 allometric exponents in our study are consistent with previously reported values
(Bregante et al. , 1999). The larger value of 1.1 for ciprofloxacin (all species) and smaller
value of 0.5 (mammals) for enrofloxacin may be due to the route of el imination or
differences in plasma protein binding.
Enrofloxacin and ciprofloxacin are excreted by renal and hepatobiliary pathways
in mammals (Lode et al. , 1989). Renal excretion is variable; however, most quinolones,
including enrofloxacin and ciprofloxacin, undergo glomerular filtration and active tubular
secretion (Vance-Bryan et al., 1990; Vancutsem et al., 1990; Brown 1996). Elimination
of enrofloxacin and ciprofloxacin given to trout, carp, African catfish , and rainbow trout
occurs via a passive diffusion process in the glomerulus and the gills, which results in a
longer half-life of elimination (Nouws et al. , 1988b; Bowser et al. , 1992).
Enrofloxacin has a low hepatic extraction ratio (Sorgel 1989). Therefore , hepatic
clearance of enrofloxacin is influenced by plasma protein binding and intrinsic clearance,
which is affected by the level of hepatic enzyme activity. No studies have shown that
fluoroquinolones are so highly bound that this limits distribution to tissues . However,
there does seem to be some variation between species. Ciprofloxacin plasma protein
binding is 30% in humans (Lettieri et al., 1992); 14% in goats (Garcia Ovando et al.,
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2000); 33% in rats (Siefert et al., 1986); 23% in monkeys (Siefert et al., 1986) 24% in
pigs (Nouws et al., 1988a); 70% in calves (Nouws et al., 1988a); and 44% in dogs (Villa
et al., 1997). Aramayona et al., (1996) found a two-fold difference in plasma protein
binding between rabbits that were pregnant (30%) and those that were not (15%). Carp ,
catfish and trout have very similar plasma protein binding of 22% , 20% and 23% (Nouws
et al. , 1988b). Enrofloxacin seems to have the same type of variation between species
for plasma protein binding as that of ciprofloxacin . For instance, plasma protein binding
in cows is 35% (Kaartinen et al., 1995); in camels 17-24% (Gavrielli et al. , 1995); in dogs
15-27% (Papich & Riviere 2001 ); in horses 22% (Villa et al., 1997); and in pigs 27%
(Villa et al., 1997). Similar plasma protein binding occurs in a few species : in sheep , the
value is 69% (Papich & Riviere 2001 ); in rats 50% (Papich & Riviere 2001 ); and in
rabbits 35-50% (Papich & Riviere 2001 ).
Data was not corrected for plasma protein binding in our analyses since it was
not available for all species that were studied. Thus , this may have influenced the half
life and clearance analyses . It is also difficult to compare results of studies in which
protein binding was measured because of differences among laboratories and variations
in methods used (Zlotos et al. 1998b). Bregante et al. (1999) did correct for plasma
protein binding in their study by using the plasma free fraction, which may be why they
had a better clearance allometric exponent for mammals. The data in the Bregante et al.
(1999) study also originated from a single laboratory, which decreases the amount of
variability compared to a study where data was derived from multiple sources.
Other possible reasons for variations in the exponents are the various conditions
(lactating , pregnant, sex, breed , age, fasted or fed) of the animals used in the various
studies. Nouws et al. (1988a) suggested that the age of the animal (maturity of renal
function and metabolic capacity of liver) as well as breed difference may have affected
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the ciprofloxacin plasma concentrations and thus its pharmacokinetic parameters.
Aramayona et al. (1996) indicated that lactation and associated factors in rabbits could
affect the binding of ciprofloxacin to plasma proteins. Lactation may be associated with
different hormone levels that affect plasma protein binding. Siefert et al. (1986) noted
that possible differences in ciprofloxacin metabolism existed between male and female
rats . This may also be true in other species and could influence pharmacokinetic
parameters of interest.
The allometric exponent for volume of distribution was 1.09 (all species) and 0.98
(mammals) for ciprofloxacin, while enrofloxacin exponents were 0.91 and 0.89 for both
the all species and mammals groups, which is consistent with previously reported values
(Bregante et al. , 1999).
We concluded that volume of distribution is proportional to body weight for both
drugs, while the elimination half-life for ciprofloxacin and enrofloxacin independent of
body weight. The allometric exponent for clearance of both drugs suggests a differing
rate of metabolism or extent of elimination in the species studied. Thus , our study
supports the allometric modeling of enrofloxacin and ciprofloxacin across species using
volume of distribution, but not half-life. The use of clearance is less conclusive, and
further experimental allometric studies are indicated. Allometry can be an important tool
for dose extrapolation of certain classes of drugs; however, this should be done only
when strong correlations are found .

42
Abadia, A. R. Aramayona, J. J., Munoz, M. J. Pia Delfina, J. M. , Daez, M. P., Bregante,
M. A. 1994. Disposition of ciprofloxacin following intravenous administration in dogs.
Journal of Veterinary Pharmacology and Therapeutics 17:384-388.
Anadon , A., Martinez-Larranaga, M. R., Diaz, M. J. Fernandez-Cruz, M. L. , Martinez, M.
A. , Frejo, M. T. , Martinez, M., Iturbe, J. & Tafur, M. 1999 Pharmacokinetic variables
and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. American Journal
of Veterinary Research 60:1377-1382.
Anadon , A., Martinez-Larranaga, M. R., Diaz, M. J., Bringas, P. , Martinez, M.A. ,
Fernandez-Cruz, M. L., Fernandez, M. C., Fernandez, R. 1995. Pharmacokinetics
and residues of enrofloxacin in chickens. American Journal of Veterinary Research 56 :
501-505.
Aramayona, J . J. , Mora, J., Fraile , L. J., Garcia, M. A. , Abadia , A. R., Bergante, M. A.
1996. Penetration of enrofloxacin and ciprofloxacin into breast milk, and
pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. American
Journal of Veterinary Research 57: 547-553.
Baggot, J. D. 1977. Principles of Drug Disposition in Domestic Animals. W.8. Saunders,
Philadelphia., pp. 20-45.
Baggot, J. D. 1980. Distribution of antimicrobial agents in normal and diseased
animals. Journal of the American Veterinary Medical Association 176:1085-1090.
Baggot, J. D. 1990. Pharmacokinetic-pharmacodynamic relationship. Annales de
Recherches Veterinaries 21 (Suppl) :29-40.
Bailey, T . A., Sheen , R. S., Silvanose, C., Samour, J. H., Garner, A. 1998.
Pharmacokinetics of enrofloxacin after intravenous, intramuscular and oral
administration in houbara bustard (Chlamydotis undulata macqueenii). Journal of
Veterinary Pharmacology and Therapeutics 21 : 288-297.
Benet, L. Z. Kroetz, D. L. , Sheiner, L. 8. 1996. Pharmacokinetics. In The
Pharmacological Basis of Therapeutics. 9th edn. Eds Gilman, A.G., Molinoff, P. 8 .,
Ruddon , R. W. New York, McGraw-Hill, pp. 18-22.
Bergan, T. , Dalhoff, A., Rohwedder, R. 1988. Pharmacokinetics of ciprofloxacin .
Infection 16 (Suppl 1): S3-S13 .
Bergan, T., Thorsteinsson , S. 8., Solberg , R., Bjornskau, L. , Kolstad , I. M., Johnsen , S.
(1987) Pharmacokinetics of ciprofloxacin : intravenous and increasing oral doses . The
American Journal of Medicine 82:97-102.
Bermingham, E. C. , Papich , M. G., Vivrette, S. L. 2000. Pharmacokinetics of
enrofloxacin administered intravenously and orally to foals. American Journal of
Veterinary Research 61: 706-709.

43
Bowser, P.R., Wooster, G. A. , St Leger, J., Babish, J. G. 1992. Pharmacokinetics of
enrofloxacin in fingerling rainbow trout. Journal of Veterinary Pharmacology and
Therapeutics 15:62-71 .
Boxenbaum , H. 1982. Interspecies scaling allometry, physiological time, and the ground
plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 10:201207.
Bregante, M. A. , Saez, P., Aramayona , J. J., Fraile, L. , Garcia, M. A. , Solans, C. 1999.
Comparative pharmacokinetics of enrofloxacin in mice, rats , rabbits , sheep and cows .
American Journal of Veterinary Research 60:1111-1116.
Brodie, B. B. 1964. Of mice, microsomes and men . Pharmacologist 6: 12-26.
Brown , S. A. 1996. Fluoroquinolones in animal health . Journal of Veterinary
Pharmacology and Therapeutics 19:1-14.
Cabanes , A. , Arboix, M., Garcia Anton , J. M., Reig , F. 1992. Pharmacokinetics of
enrofloxacin after intravenous and intramuscular injection in rabbits . American Journal
of Veterinary Research 53:2090-2093 .
Calder, W . A. 1984. Size, Function and Life History. Harvard University Press ,
Cambridge
Catchpole , C., Andrews , J. , Woodcock, J. , Wise, R. 1994. The comparative
pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400mg iv and
750mg po. Journal of Antimicrobial Chemotherapy 33: 103-110.
Cester, C. C., Toutain , P. L. 1997. A comprehensive model for enrofloxacin to
ciprofloxacin transformation and disposition in dog . Journal of Pharmaceutical
Sciences 86:1148-1155.
Christensen , J.M ., Smith, B. B, Murdane, S. B., Hollingshead , N. 1996. The
disposition of five therapeutically important antimicrobial agents in llamas. Journal of
Veterinary Pharmacology and Therapeutics 19:431-438.
Deppermann , K. M., Boeckh , M. , Grineisen , S. , Shokry, F. , Borner, K., Koeppe , P.,
Krasemann , C., Wagner, J., Lode, H. 1989. Brief report: Combination effects of
ciprofloxacin , clindamycin, and metronidazole intravenously in volunteers . The
American Journal of Medicine 87:46S-48S.
Dudley, M. N., Ericson , J., Zinner, S. H. 1987. Effect of dose on serum
pharmacokinetics of intravenous ciprofloxacin with identification and characterization
of extravascular compartments using noncompartmental and compartmental
pharmacokinetic models. Antimicrobial Agents and Chemotherapy 31 : 1782-1786.
Dudley, M. N. Mandler, H. D., Gilbert, D., Ericson, J., Mayer, K. H., Zinner, S. H. 1987.
Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin . The American
Journal of Medicine 82:363-368.

44
Dutton, G. J. 1980. Glucuronidation of Drugs and Other Compounds . CRC Press, Boca
Raton. pp. 127-128.
Dutton, G. J., Wishart, G. J., Leakey, J.E. A. , Goheer, M.A. 1977. Conjugation with
glucuronic acid and other sugars. In Drug Metabolism from Microbe to Man, Eds Park,
D. V. & Smith, R. L. London, Taylor & Francis Ltd., pp. 57.
Elmas, M., Tras, B., Kaya, S., Bas, A. L., Yazar, E., Yarsan , E. 2001 . Pharmacokinetics
of enrofloxacin after intravenous and intramuscular administration in Angora goats. The
Canadian Journal of Veterinary Research 65:64-67.
Garcia-Ovando, H., Lunders, C., Gorla, N., Errecalde, C., Prieto, G. 1997. Intravenous
pharmacokinetics of enrofloxacin and ciprofloxacin in broiler chickens. Journal of
Veterinary Pharmacology and Therapeutics 20:203.
Garcia Ovando, H., Gorla, N., Luders, C., Poloni, G., Errecalde, C., Prieto, G., Puelles , I.
1999. Comparative pharmacokinetics of enrofloxacin and ciprofloxacin in chickens.
Journal of Veterinary Pharmacology and Therapeutics 22:209-212.
Garcia Ovando, H., Gorla, N., Poloni, G., Trotti , N., Prieto, G., Errecalde, C. 2000.
Intravenous pharmacokinetics of ciprofloxacin in goats. International Journal of
Antimicrobial Agents 15:77-79.
Gavrielli, R., Yagil, R., Ziv, G., Creveld, C. V., Glickman , A. 1995. Effect of water
deprivation on the disposition kinetics of enrofloxacin in camels. Journal of Veterinary
Pharmacology and Therapeutics 18:333-339.
Harron, D. W. G., Nation, G., Tinson, A.H., Dhanasekharan, S., Sheen, R. 1997.
Effects of administration routes and dose on the pharmacokinetics of enrofloxacin in
young and mature camels. Journal of Veterinary Pharmacology and Therapeutics 20:
54-55.
Helmick, K. E., Boothe, K. M., Jensen, J. M. 1997. Disposition of single-dose
intravenously administered enrofloxacin in Emus (Dormaius Novaehollandiae). Journal
of Zoo and Wildlife Medicine 28:43-48.
Kaartinen, L., Salonen, M., Alli, L., Pyorala, S. 1995 Pharmacokinetics of enrofloxacin
after single intravenous, intramuscular and subcutaneous injections in lactating cows.
Journal of Veterinary Pharmacology and Therapeutics 18:357-362.
Kaartinen, L., Pyorala, S., Moilanen , M., Raisanen, S. 1997a. Pharmacokinetics of
enrofloxacin in newborn and one-week-old calves. Journal of Veterinary Pharmacology
and Therapeutics 20:479-482.
Kaartinen , L., Panu, S., Pyorala, S. 1997b. Pharmacokinetics of enrofloxacin in horses
after single intravenous and intramuscular administration. Equine Veterinary Journal 29:
378-381.

45
Kietzmann, M., Knoll, U., Glunder, G. 1997. Pharmacokinetics of enrofloxacin and
danofloxacin in broiler chickens. Journal of Veterinary Pharmacology and Therapeutics
20:202.
Knoll , U., Glunder, G., Kietzmann , M. 1999. Comparative study of the plasma
pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler
chickens . Journal of Veterinary Pharmacology and Therapeutics 22:239-246 .
Kung , K., Riond , J. L., Wanner, M. 1993. Pharmacokinetics of enrofloxacin and its
metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in
dogs. Journal of Veterinary Pharmacology and Therapeutics 16:462-468.
Lettieri, J. T. , Rogge, M. C., Kaiser, L., Echols, R. M. , Heller, A.H . 1992.
Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.
Antimicrobial Agents and Chemotherapy 36 :993-996.
Ljungberg, B., Nilsson-Ehle, I. 1988. Pharmacokinetics of intravenous ciprofloxacin at
three different doses . Journal of Antimicrobial Chemotherapy 22 :715-720.
Lode, H., Hoffken, G., Olschewski , P., Sievers, B., Kirch , A. , Borner, K. , Koeppe , P.
1988. Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin .
Journal of Antimicrobial Chemotherapy 22 (Supple C):73-79 .
Lode , H. , Hoffken , G. , Borner, K., Koeppe , P. 1989. Unique aspects of quinolone
pharmacokinetics. Clinical Pharmacokinetics 16 (Suppl 1):1-4.
Martinez-Larranaga, M. R. , Diaz, M. J. , Martinez, M. A. , Frejo, M. T., Bringas, P.,
Anadon , A. 1997. Bioavailability of enrofloxacin after subcutaneous administration in
cattle. Journal of Veterinary Pharmacology and Therapeutics 20:52.
Martinsen, B., Horsberg, T. E. 1995. Comparative single-dose pharmacokinetics of
four quinolones, oxolinic acid . flumequine, sarafloxacin and enrofloxacin in Atlantic
salmon ( Sa/mo salar) held in seawater at 10° C. Antimicrobial Agents and
Chemotherapy 39: 1059-1064.
Mellett, L. B. 1969. Comparative drug metabolism. Progressive Drug Research 13: 139169.
Mengozzi, G., lntorre, L., Bertini, S., Soldani, G. 1996. Pharmacokinetics of
enrofloxacin and its metabolite ciprofloxacin after intravenous and intramuscular
administrations in sheep. American Journal of Veterinary Research 57 :1040-1043.
Monlouis , J. D., De Jong, A. , Limet, A. , Richez, P. 1997. Plasma pharmacokinetics
and urine concentrations of enrofloxacin after oral administration of enrofloxacin in
dogs. Journal of Veterinary Pharmacology and Therapeutics 20:61-63 .
Munoz, M. J., Lloveria, P., Santos, M. P., Abadia , A. R., Aramayona, J. J., Bregante,
M. A. 1996. Pharmacokinetics of ciprofloxacin in sheep after single intravenous or
intramuscular administration . Veterinary Quarterly 18:45-48.

46
Nielson, P., Gyrd-Hansen, N. 1997. Bioavailability of enrofloxacin after oral
administration to fed and fasted pigs. Pharmacology and Toxicology 80:246-250.
Nix, D. E., Spivey, J.M ., Norman, A., Schentag, J. J. 1992. Dose-ranging
pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous
doses. The Annals of Pharmacotherapy 26:8-10.
Nouaille-Degorce, B., Veau, C., Dautrey, S., Tod, M., Laouari, D., Carbon, C., Farinotti ,
R. 1998. Influence of renal failure on ciprofloxacin pharmacokinetics in rats.
Antimicrobial agents and Chemotherapy 42:289-292.
Nouws, J. F. M., Mevius, D. J., Vree, T. B., Baars, A.M., Laurensen, J. 1988.
Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following
intravenous and oral administration to calves and pigs. The Veterinary Quarterly 10:
156-163.
Nouws, J. F. M., Grandel, J. L., Schutte, A. R., Laurensen, J. 1988. Pharmacokinetics
of ciprofloxacin in carp African catfish and rainbow trout. The Veterinary Quarterly 10:
211-216.
Outman, W. R., Nightingale, C. H. 1989. Metabolism and the fluoroquinolones.
American Journal of Medicine 87:375-425.

loo

Papich, M.G., Riviere J.E. 2001. Fluoroquinolone antimicrobial drugs. In Veterinary
Pharmacology and Therapeutics, Ed. Adams, R. Ames, Iowa State University Press, pp.
898-917.
Pashov, D. A. , Lashev, L. D., Matev, I. B., Kanelov, I. N. 1997. Interspecies
comparisons of plasma half-live of trimethoprim in relation to body mass. Journal of
Veterinary Pharmacology and Therapeutics 20:48-53 .
Post, L. 0 ., Cope, C. V., Farrell, D. E., Baker, J. D., Myers, M.J. 2002. Influence of
Porcine Actinobacil/us p/europneumoniae infection and dexamethasone on the
pharmacokinetic parameters of enrofloxacin. The Journal of Pharmacology and
Experimental Therapeutics 301 :217-222.
Pozzin, 0 ., Harron, D.W.G., Nation, G., Tinson, A.H., Sheen, R. & Dhanasekharan, S.
1997 Pharmacokinetics of enrofloxacin following intravenous/intramuscular/oral
administration in Nedji sheep. Journal of Veterinary Pharmacology and Therapeutics
20 :60.
Rao, G. S., Ramesh, S., Ahmad, A. H., Tripathi, H. C., Sharma, L. D. , Malik, J. K. 2000.
Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and
its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats.
Journal of Veterinary Pharmacology and Therapeutics 23:365-372.

47
Richez, P. Monlouis, J. D., Dellac, 8 ., Daube, G. 1997. Validation of a therapeutic
regimen for enrofloxacin in cats on the basis of pharmacokinetic data. Journal of
Veterinary Pharmacology and Therapeutics 20:152-153.
Richez, P. , Marner, A. P., De Jong , A. , Monlouis, J. D. 1997. Plasma pharmacokinetics
of parenterally administered danofloxacin and enrofloxacin in pigs. Journal of Veterinary
Pharmacology and Therapeutics 20:41 -42.
Riond , J. L. , Riviere , J. E. 1990. Allometric analysis of doxycycline pharmacokinetic
parameters. Journal of Veterinary Pharmacology and Therapeutics 13:404-407.
Riviere, J.E., Martin-Jimenez, T., Sundlof, S. F., Craigmill, A. L. 1997. Interspecies
allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary
and laboratory animal species. Journal of Veterinary Pharmacology and Therapeutics
20:453-463.
Rowland , M. 1986. Physiologic pharmacokinetic models and interanimal species scaling .
In Pharmacokinetics: Theory and Methodology. Eds Rowland, M. & Tucker, G.T.
Pergamon Press , New York pp . 82-86.
Seifert, H. M., Maruhn , D., Maul, W ., Forster, D., Ritter, W. 1986. Pharmacokinetics of
ciprofloxacin. Arzneimittel Forschung 36:1496-1502.
Sorgel, F. 1989. Metabolism of gyrase inhibitors. Reviews of Infectious Diseases 11 :
S1119-S1129.
Vance-Bryan , K., Guay, D. R. P. , Rotschafer, J.C. 1990. Clinical pharmacokinetics of
ciprofloxacin. Clinical Pharmacokinetics 19:434-461 .
VanCutsem , P. M. , Babish, J. H. G. , Schwark, W . S. 1990. The fluoroquinolone
antimicrobials structure, antimicrobial activity, pharmacokinetics , clinical use in
domestic animals and toxicity. The Cornell Veterinarian 80:173-186.
Villa , R. , Prandini, E., Calon i, F., Carli , F. 1997. Serum protein binding of some
sulphonamides, quinolones and fluoroquinolones in farm and domestic animals.
Journal of Veterinary Pharmacology and Therapeutics 20(Suppl.1 ):34-35.
Williams, R. T. 1973. Inter-species variations in the metabolism of xenobiotics. The
Eight CIBA Medal Lecture 2:361-377.
Wingender, W. , Graefe, K. H., Gau, W., Forster, D., Beermann, D., Scacht, P. 1984.
Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy
volunteers . European Journal of Clinical Microbiology 3:355-359.
Zeng , Z., Fung , K. 1997. Effects of experimentally induced Escherichia coli infection
on the pharmacokinetics of enrofloxacin in pigs. Journal of Veterinary Pharmacology
and Therapeutics 20:39-40.

48
Zlotos, G., Bucker, A., Kinzig-Schippers, M., Sorgel, F., Holzgrabe, U. 1998a. Plasma
protein binding of gyrase inhibitors. Journal of Pharmaceutical Sciences 87:215-220.
Zlotos, G., Oehlmann, M. , Nickel, P., Holzgrabe, U. 1998b. Determination of protein
binding of gyrase inhibitors by means of continuous ultrafiltration. Journal of
Pharmaceutical and Biomedical Analysis 18:847-858.

49

PART Ill: DETERMINATION OF BUFURALOL AND 1'-HYDROXYBUFURALOL IN
PORCINE MICROSOMAL PREPARATIONS
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Chapter 1: Abstract
A simple, rapid and sensitive HPLC analysis of bufuralol and 1'-hydroxbufuralol
in porcine microsome samples is described . Chromatography was performed on a
Resolve C 18 column using a mobile phase of 10 mM sodium perchlorate pH
2.45:acetonitrile (48:52). Fluorescence was measured at excitation 252 nm and emission
302 nm. The procedure produced a linear curve for the concentration range 10-1500
ng/ml. This assay produced rapid , accurate and repeatable results .
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Chapter 2: Introduction
The cytochrome P450 monooxygenase enzyme system is important in terms of
its catalytic versatility and sheer number of chemical agents it is capable of detoxifying,
or activating to reactive intermediates (Guengerich, 1992;Parkinson, 1996). P450
enzymes are concentrated mainly in the liver endoplasmic reticulum (microsomes), but
they are located in virtually all other tissues. These enzymes activate xenobiotics,
including drugs that are toxic or that produce tumorigenic metabolites. The enzymes
also detoxify xenobiotics, and aid in determining intensity and duration of action of
drugs. Thus, it is essential to establish the activity and regulation of the P450 system for
species selected for pharmacological and toxicological studies. In addition, impaired
drug disposition in food-producing animals may lead to changes in residue levels of
veterinary drugs and other xenobiotics in edible tissues, milk, or eggs. Much of the
information known about P450 enzymes comes from studies conducted in rodents.
However, the pig is becoming a popular alternative to traditional non-rodent species in
pharmacological and toxicological testing (Skaanild and Friis, 1999). The information on
the P450 enzyme system for this food animal species is limited.
P450 enzymes are mainly responsible for phase I metabolism, which adds or
exposes polar functional groups on a lipophilic substrate. In the investigation of P450
enzyme-mediated xenobiotic metabolism, individual forms of P450 enzymes have been
found to catalyze specific reactions with specific substrates. Thus, characterizing these
specific enzyme activities allows their use as probes in drug metabolism studies. To
date, at least one marker activity exists for the majority of human P450 enzymes (Sharer
et al., 1995). The conversion of bufuralol to 1'-hydroxybufuralol is one of the methods
used to characterize human cytochrome P450 enzyme CYP2D6 activity; but limited
information exists in other mammalian species.
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There are a few high performance liquid chromatography (HPLC) methods
(Boobis et al., 1985; Kronbach et al. , 1987; Lee and Moochhala, 1989; Guang and Lang
Li , 1996) used in the analysis of bufuralol and its metabolite. However, one method
(Guang and Lang-Li , 1996) uses normal phase chromatography, while another method
(Boobis et al. , 1985) involves the use of at-butyl ether extraction. A third method (Lee
and Moochhala, 1989) does not report any validation for the procedure and uses
tetrahydrofuran in the mobile phase, while another method (Kronbach et al. , 1987) uses
an expensive fluorometer and no internal standard . These methods (Boobis et al. , 1985;
Kronbach et al. , 1987; Lee and Moochhala , 1989; Guang and Lang-Li , 1996) involve the
analysis of human or rat microsome samples, but not porcine microsomal samples.
This article describes a rapid and efficient method for the in vitro analysis of 1'
hydroxybufuralol and bufuralol. Th is procedure provides a quick analysis that may
facilitate characterization of P450 enzyme metabolism in the pig.
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Chapter 3: Materials and Methods
Reagents and Standards
Acetonitrile was "HPLC" grade, while sodium perchlorate, and perchloric acid
were reagent grade. All were purchased from Fisher Scientific (Pittsburgh , PA, USA).
Bufuralol and 1'-hydroxbufuralol were purchased from Gentest (Woburn , MA, USA).
Chloropropamide (internal standard) glucose 6-phosphate (G-6-P), glucose 6-phosphate
dehydrogenase (G-6-PDH), and ~-nicotinamide adenine dinucleotide phosphate (NADP)
were purchased from Sigma Chemical Company (St. Louis, MO, USA).
Stock standard solutions of bufuralol (100 , 5 and 1 µg/ml) and 1'
hydroxybufuralol (100 , 5, and 1 µg/ml) were prepared in water and stored at 4°C. The
solutions were stable for six months. Working standards were prepared fresh daily by
dilution of the stock standards. A stock standard solution of chlorpropamide (300 µg/ml)
was prepared in methanol and stored at 4°C. This solution was also stable six months .
Apparatus
The analytical system consisted of a 626 solvent delivery system, a model 717
WISP autosampler, a 470 fluorescence detector and a computer equipped with
Millennium software (Waters, Milford , MA, USA). The column was a Resolve C18 ( 5 µm
3.9 x 150 mm) equipped with a C 18 Guard-Pak precolumn insert (Waters, Milford . MA,
USA).
Chromatography
The mobile phase was an isocratic mixture of 10 mM sodium perchlorate:
acetonitrile (48:52). The pH of the sodium perchlorate solution was adjusted to 2.45 with
concentrated perchloric acid . It was prepared fresh daily using double-distilled
deionized water, filtered (0 .22 µM) and degassed before use. Flow rate was 1 ml/min for
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the first four minutes, then ramped to 2.0 ml/min over 1.5 min , and maintained for 6 min
then decreased back to 1 ml/min over 1 min . Column temperature was ambient and
fluorescence was measured at an excitation 252 nm and emission 302 nm. All
chromatograms were obtained with the following fluorometric conditions: gain 1OX,
attenuation 1, and filter time constant 0.5 s.
Sample Treatment
Spiked samples were prepared by addition of appropriate volumes of both
bufuralol and 1'-hydroxybufuralol. The internal standard , chlorpropamide (100 µI of a
300 µg/ml) was added and appropriate amounts of the solutions used in microsomal
preparation were added to produce a 0.5 ml final volume . Samples were vortex-mixed
and a 125 µI sample was injected onto the liquid chromatograph.
Microsomal samples were prepared using Lake's ( 1984) ultracentrifugation
method . Incubation mixtures contained 0.5 mg of microsomal protein, 100 mM
phosphate buffer at pH 7.4 containing 6 mM magnesium chloride , 1 mM EDTA, and a
NADPH-generating system (1 mM NADP, 10 mM G-6-P and 0.7 U of G-6-PDH) in a total
volume of 0.5 ml. Incubation mixtures contained bufuralol and inhibitors and the
reactions were initiated by addition of the NAOPH-generating system after a 5 min pre
incubation step at 37°C. Reactions were quenched with 0.1 ml of ice cold acetonitrile
after 10 min in a 37°C shaking water bath , and were then placed on ice for 1 hour.
Samples were centrifuged at 16000 g for 15 min. The supernatants were removed and
stored at -80°C until analysis could be preformed . Reaction rates were linear with
incubation time under these conditions. Frozen samples were thawed on ice and vortex
mixed before use. Chlorpropamide (100 µI of a 300 µg/ml) was added to a 0.5 ml
microsome sample and vortex-mixed . Those samples containing particulates were
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centrifuged for 5 min at 16,000 gin an Eppendorf centrifuge (Brinkman Instruments,
New York, NY, USA). A 125 µI aliquot of the supernatant was injected onto the liquid
chromatograph .
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Chapter 4: Results

A blank chromatogram for a microsomal sample with no drugs added is shown in
Figure 3-1 with no interfering peaks. The chromatogram in Figure 3-2 is a porcine liver
microsome sample after incubation with 10 µmole of bufuralol. Retention times for
chlorpropamide , 1'-hydroxbufuralol, and bufuralol were 2.73, 5.00 and 9.94 min ,
respectively. The chromatogram in Figure 3-3 is a 250 ng/ml standard with retention
times of 2.98, 4.80 and 9.80 min. There is a small peak that elutes immediately prior to
chlorpropamide in all of the chromatograms. This is a contaminant of chlorpropamide ,
which does not interfere with elution of the other compounds .
This method produced a linear curve for the concentration range of 10-1500
ng/ml for bufuralol and its metabolite, with correlation coefficients ranging from 0.998 to
0.999 for both compounds . Replicate analyses performed on the same day for
microsomal samples spiked with specific concentrations of bufuralol produced
coefficients of variation (C.V.) of 9.6% for 40 ng/ml, 1.4% for 700 ng/ml and 2.2% for
1100 ng/ml. The metabolites' C.V. was 2.5%, 3.3%, and 2.5% at the same
concentrations (Table 3-1 ).

Table 3-1. Intra-assay precision for bufuralol and 1'-hydroxybufuralol (n = 4)
Concentration
Bufuralol
Coefficient of
Hydroxybufuralol
Coefficient of
Added (ng/ml)
Concentration
variation(%)
concentration
variation(%)
measured (ng/ml)
measured (ng/ml)
mean±SD
mean±SD
2.5
40
39±4
9.5
38±1
3.3
700
688±9
1.4
673±22
2.6
1100
1080±23
2.2
1095±28
SD = Standard deviation
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Figure 3-1. Chromatogram of microsomal sample with no drugs added .
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Figure 3-2. Chromatogram of a porcine microsomal sample after incubation with
10 µM
of bufuralol for 10 min. Peaks: 2.52 =chlorpropamide contaminate; Chlorpro =
chlorpropamide; Buf-OH = 1'-hydroxybufuralol; Buf = bufuralol.
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Figure 3-3. Chromatogram of a 250 ng/ml standard. Peaks: 2.73= chlorpropamide
contaminate; Chlorpro = chlorpropamide; Buf-OH = 1'-hydroxybufura lol ; Buf = bufuralol.
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Table 3-2. Inter-assay precision for bufuralol and 1'-hydroxybufuralol (n = 4)
Concentration
Bufuralol
Coefficient of
Hydroxybufuralol
Coefficient of
added (ng/ml)
concentration
variation (%)
concentration
variation (%)
measured n /ml
measured n /ml
10
9
4.7
10
2.1
25
26
7.7
24
4.8
50
48
6.3
48
8.3
100
96
100
2.0
11.4
250
242
5.0
243
4.9
500
448
4.2
470
1.9
800
768 .
4.7
798
3.4
991
1.9
1000
952
5.7
1500
1354
3.8
1457
2.4

Day-to-day variability for microsomal replicates is shown in Table 3-2. The mean
recoveries of bufuralol were 90%, 104%, 96% , 100%, 97%, 90%, 96%, 95% , and 90%
for 10, 25 , 50, 100, 250, 500, 800, 1000, and 1500 ng/ml, respectively. Mean recoveri es
of 1'-hydroxybufuralol were 95%, 97%, 95%, 96%, 97%, 94%, 100%, 99% , and 97% for
10, 25, 50, 100, 250, 500, 800, 1000, and 1500 ng/ml. The detection limit for both
bufuralol and its hydroxymetabolite was 1 ng/ml. Th is represents a peak approximately
three times baseline noise. No interference with the chromatographic procedure was
observed from numerous drugs and chemicals used in inhibition studies .
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Chapter 5: Discussion
To be useful for characterization of enzyme metabolism studies a method should
be simple, rapid , sensitive and reproducible . Such an HPLC assay, utilizing
fluorescence detection , has been developed to investigate the 1'-hydroxylation of
bufuralol by microsomal fractions of porcine liver. The assay is sensitive, specific and
reproducible , with a high recovery of the metabolite.
The detection limits and recoveries for 1'-hydroxybufuralol and bufuralol are
equal to or better than existing methods for extraction and analysis of the compounds.
However, Kronbach 's (1987) method has a better limit of detection than our method ,
which is 0.1 ng/ml with a 100 µI injection volume and a 4 to 1 signal to noise ratio. This
is due to the use of a more expensive dual monochromator fluorometer capable of
higher sensitivities than are possible with a typical HPLC fluorescence detector. Use of
chlorpropamide as the internal standard corrects for intra- and inter-assay variability in
the method . It was discovered that due to the composition of the sample, injection filters
could become clogged and thus affect the injection volume . Although the systems were
cleaned at the end of each analysis in order to prevent this , an internal standard was
added to prevent any changes in concentration from occurring due to this event. To
prevent clogg ing of the column it was cleaned with dimethylsulfoxide (DMSO):water
(1 :1) injections after every 300 sample injections . With proper column cleaning this is a
rugged procedure with the column still in use after 1500 injections .
This method was developed in order to determine the metabolism of bufuralol in
porcine microsome samples. Our procedure eliminates the use of liquid-liquid
extractions and normal phase chromatography. This method has been applied to
metabolism studies in porcine microsomes involving bufuralol in this laboratory. In
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conclusion, a simple, rapid , sensitive and useful HPLC procedure has been developed
for analysis of 1'-hydroxybufuralol and bufuralol in microsome samples.
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Chapter 1: Abstract
A simple, accurate and sensitive HPLC analysis of 6-hydroxychlorzoxazone and
chlorzoxazone in porcine microsome samples is described. Chromatography was
performed on a YMC-Pack 00S-AQ column using a mobile phase of 0.05% phosphoric
acid pH 3:methanol (60 :40). UV detection was carried out at 287 nm. The procedure
produced a linear curve for the concentration range 25-2000 ng/ml. This assay
produced quick, accurate, and repeatable results .

67
Chapter 2: Introduction
The cytochrome P450 monooxygenase enzyme system is important in terms of
its catalytic versatility and the sheer number of compounds it detoxifies or activates to
reactive intermediates (Guengerich , 1992; Parkinson, 1996). The largest concentration
of P450 enzymes is located in the liver endoplasmic reticulum (microsomes), but they
are located in virtually all other tissues in the body. These enzymes activate xenobiotics
including drugs to toxic and/or tumorigenic metabolites, detoxify xenobiotics , and aid in
determining intensity and duration of action of drugs. Therefore, it is essential to
establish the activity and regulation of the P450 system for species selected for
pharmacological and toxicological studies. In addition , impaired drug disposition in food
producing animals may lead to changes in residue levels of veterinary drugs and other
xenobiotics in edible tissues , milk, or eggs. There is also concern about the increase in
development of drug resistant bacterial strains in food animals. Much of the information
known about P450 comes from studies conducted in rodents. However, the pig is
becoming a popular alternative to traditional non-rodent species in pharmacological and
toxicological testing (Skaanild and Friis, 1999). The information on the P450 system for
this species is limited.
P450 enzymes are mainly responsible for phase I metabolism, which adds or
exposes polar functional groups on a lipophilic substrate. In the investigation of P450
mediated xenobiotic metabolism, individual forms of P450 have been found to catalyze
specific reactions with certain substrates, thus designating these activities as probes for
these forms . To date, at least one marker activity exists for the majority of human P450
forms (Sharer et al. , 1995). Cytochrome P4502E1 is a major mammalian hepatic
enzyme, which catalyzes the biotransformation of many low molecular weight
xenobiotics . However, one of the challenges to studying 2E1 has been to identify a
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model substrate that is a sensitive and specific marker for the enzyme's activity. The
conversion of chlorzoxazone (CZX) to 6-hydroxychlorzoxazone (OH-CZX) (Figure 4-1) is
one of the methods used to characterize human cytochrome P450 enzyme CYP2E1
activity both in vivo and in vitro. But limited information exists in other mammalian
species because of differences in biotransformation.
Several high performance liquid chromatography (HPLC) methods have been
developed to measure CZX and OH-CZX in biological fluids and microsomes (Peter et
al. , 1990; Thummel et al. , 1993; Chen & Yang, 1996; Haque & Stewart, 1997; Court et
al. , 1997; Chittur & Tracy, 1997; Frye et al. , 1998; Leclercq et al. , 1998; Lillibridge et al. ,
1998; Cummings et al., 2001 ; Taavitsainen et al. , 2001 ). Some of the methods involve
the use of liquid-liquid extractions (Peter et al. , 1990; Thummel et al. , 1993; Chen &
Yang , 1996; Chittur & Tracy, 1997; Leclercq et al., 1998; Lillibridge et al., 1998;
Cummings et al. , 2001; Taavitsainen et al. , 2001) while most use rat or human
microsome samples.
We describe an easy and efficient method for the in vitro analysis of OH-CZX
and CZX. This procedure provides a quick analysis that may facilitate the
characterization of P450 metabolism in the pig . This characterization may allow the pig
to be used in pharmacological and toxicological studies to determine detoxification of
xenobiotics as well as aid in determining appropriate dosages and withdrawal times of
drugs used in food animals.
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Figure 4-1 . Structures of chlorzoxazone and 6-hydroxychlorzoxazone.
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Chapter 3: Materials and Methods

Reagents and Standards
The methanol used was "HPLC" grade; phosphoric acid was reagent grade while
all other chemicals were enzyme grade. All of these chemicals were purchased from
Fisher Scientific (Pittsburgh, PA, USA). Chlorzoxazone, glucose 6-phosphate (G-6-P),
glucose 6-phosphate dehydrogenase (G-6-PDH), ~-nicotinamide adenine dinucleotide
phosphate (NADP) and phenacetin, the internal standard, were purchased from Sigma
Chemical Company (St. Louis, MO, USA). Hydroxychlorzoxazone was purchased from
RBI (St. Louis, MO, USA). Stock standard solutions of CZX (100, 5 and 1 µg/ml) and
OH-CZX (100, 5, and 1 µg/ml) were prepared in methanol and stored at 4°C. Solutions
were stable for six months. Working standards were prepared fresh daily by dilution of
the stock standards. A stock standard solution of phenacetin (100 µg/ml) was prepared
in methanol and stored at 4°C. This solution was also stable for six months. Phenacetin
is light sensitive and all solution containers were wrapped in aluminum foil.
Apparatus
The analytical system consisted of a 626 solvent delivery system, a model 717
WISP autosampler, a 996 scanning UV detector and a computer equipped with
Millennium software (Waters, Milford, MA, USA). The column was a YMC-Pack ODS
AQ (5 µm, 6 x 150 mm) equipped with a C 18 Guard-Pak precolumn insert (Waters,
Milford. MA, USA).
Chromatography
The mobile phase consisted of a mixture of (A) 0.05% phosphoric acid, pH 3.0
and (B) methanol. The mixture was pumped as a gradient starting at 60% A and 40% B
and was maintained for 12 min. Over a 2 min period the mixture changed to 58% A and
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42% B which was maintained for 5 min and then returned to initial conditions over the
final 3 min period . The system was ready for the next injection without further
equilibration . The mobile phase was prepared fresh daily using double-distilled
deionized water, filtered (0.22 µM) and degassed before use . The flow rate was 1.7
ml/min. Column temperature was ambient and UV detection was measured at 287 nm.
Sample Treatment
Spiked samples were prepared by addition of appropriate volumes of both CZX
and OH-CZX. The internal standard, phenacetin (30 µI of 100 µg/ml) was added .
Appropriate amounts of the solutions used in microsomal preparations were added to
produce a 0.5 ml final volume . Samples were vortex-mixed and a 190 µI sample injected
onto the liquid chromatograph .
Microsomal samples were prepared using Lake's (1987) ultracentrifugation
method . Incubation mixtures contained 0.5 mg of microsomal protein, 100 mM
phosphate buffer at pH 7.4 containing 6 mM magnesium chloride, 1 mM EDTA, and a
NADPH-generating system (1 mM NADP, 10 mM G-6-P and 0.7 U of G-6-PDH) in a total
volume of 0.5 ml. Incubation mixtures contained CZX and inhibitors and the reactions
were initiated by addition of the NAOPH-generating system after a 5 min pre-incubation
step at 37°C. Reactions were quenched with 0.1 ml of ice cold acetonitrile after 20 min
in a 37°C shaking water bath and then placed on ice for 1 hour. Samples were
centrifuged at 16000 g for 15 min. The supernatants were removed and stored at -80°C
until analysis could be performed. Reaction rates were linear with incubation time under
these conditions . Frozen samples were thawed on ice and vortex-mixed before use.
Phenacetin (30 µI of 100 µg/ml) was added to a 0.5 ml microsome sample and vortex
mixed . Samples, which contained particulates, were centrifuged for 5 min at 16,000 g in
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an Eppendorf centrifuge (Brinkman Instruments, New York, NY, USA). A 190 µI aliquot
of the supernatant was injected onto the liquid chromatograph.
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Chapter 4: Results

A blank chromatogram for a microsomal sample is shown in Figure 4-2 with a
large peak at 2.32 min and a small peak at 2.95 min . These peaks are the result of
NADPH generating solution used in the preparation of the microsome sample; however,
they do not interfere with the peaks of interest. The x-axis on chromatograms 4-3 and 44 start roughly at 5 min in order to eliminate the large NADPH peak and provide a better
image. The chromatogram in Figure 4-3 represents a 500 ng/ml standard. The retention
times were 6.79, 11.78 and 20.28 min for OH-CZX, phenacetin and CZX, respectively.
The chromatogram in Figure 4-4 represents a porcine liver microsome sample after
incubation with 10 µM of CZX. Retention times for OH-CZX, phenacetin and CZX were
6.84, 11.92 and 20.67 min.
This method produced a linear curve for the concentration range of 25 - 2000
ng/ml for CZX and its metabolite, with correlation coefficients ranging from 0.998 to
0.999 for both compounds . Replicate analyses performed on the same day for
microsomal samples spiked with specific concentrations of CZX produced coefficients of
variation (C.V.) of 4.6% for 60 ng/ml, 2.9% for 800 ng/ml and 1.8% for 1700 ng/ml. The
metabolites' C.V. was 3.2%, 0.3% , and 0.9% for the same concentrations (Table 4-1 ).

Table 4-1. Intra-assay precision for chlorzoxazone and 6-hydroxychlorzoxazone (n = 4)
Coefficient of
OH-CZX
Coefficient of
CZX
Concentration
variation (%)
concentration
variation (%)
Concentration
added (ng/ml)
measured (ng/ml)
measured (ng/ml)
mean±SD
mean±SD
3.2
63±2
4.6
60±3
60
0.3
761 ±3
2.9
766±22
800
0.9
1749±16
1.8
1700
1761 ±31
SD = Standard deviation
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Figure 4-2. Blank microsome chromatogram with no drug added. Peaks 2.32 and 2.95
result from microsomal generating solution.
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Table 4-2. Inter-assay precision for chlorzoxazone and 6-hydroxychlorzoxazone (n = 4)
Coefficient of
OH-CZX
Coefficient of
CZX
Concentration
variation(%)
Concentration
variation(%)
concentration
added (ng/ml)
measured n /ml
measured n /ml
11
26
2.1
24
25
2.1
48
7.8
51
50
5.3
94
8.3
102
100
6.6
244
1.9
243
250
477
5.1
2.6
491
500
6.0
975
1.5
989
1000
2.0
1989
6.0
1897
2000

Day-to-day variability for microsomal replicates appears in Table 4-2. Mean recoveries
of CZX were 96% , 101 %, 102%, 97%, 98%, 99%, and 95 % for 25, 50 , 100, 250, 500,
1000, and 2000 ng/ml. Mean recoveries of OH-CZX were 104%, 96%, 94% , 98%, 95% ,
98%, and 99% for 25, 50, 100, 250, 500, 1000, and 2000 ng/ml. The detection limit for
CZX was 20 ng/ml and its metabolite was 10 ng/ml. This represents a peak
approximately three times that of baseline noise.
Numerous drugs and chemicals used in inhibition studies were tested for
interference with the chromatographic procedure (Table 4-3). Initially, quinidine was
found to co-elute with OH-CZX however, using the current chromatography and a
change of pH to 3.2 eliminated this problem. Furafylline, which is used in microsomal
assays, could interfere with the internal standard, phenacetin , but with the current
gradient there is adequate separation .
Operating under linear conditions adapted from reported procedures, (Newton et
al. , 1995; Hickman et al. , 1998) the formation of OH-CZX was easily detectable at 10 µM
as seen in Figure 4-4. Enzyme activity for the sample was 216 nmole/min/mg protein.
This was calculated by dividing the amount of product formed by incubation time and
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microsomal protein content. In this particular sample of porcine liver microsomes, the
estimated Km for the process was 43 µM .

Table 4-3 . Chemicals tested for assay interference.
Retention Times
Chemicals
7.82
Qu inidine
10.37
Furafylline
ND
7.8-Benzoflavone
ND
Diethyldithiocarbamate
ND
Ketoconazole
4.96
Ciprofloxacin
ND
Bufuralol
ND
ltraconazole
11.92
Phenacetin
2.32
NADP
2.45
Potassium phosphate
ND
Magnesium chloride
ND
Glucose-6-phosphate
ND
Glucose-6-phosphate dehydrogenase
ND= No peaks were detected.
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Chapter 5: Discussion
Enzyme metabolism studies require a method that is simple, quick, sensitive and
reproducible. An HPLC assay, utilizing UV detection, has been developed to investigate
the 6-hydroxylation of CZX by microsomal fractions of porcine liver. The assay is
sensitive, specific and reproducible , with a high recovery of the metabolite.
Because we did not use an extraction for our samples, the NADP generating
solution produced a very large peak initially. In order to prevent any interference with
OH-CZX, the mobile phase was adjusted to 60% A and 40% B. This percentage was
maintained until the elution of the internal standard in order to prevent any interference
from furafylline when it was used in microsomal preparations . We did try to optimize the
chromatography after the elution of the internal standard; however, an increase in the
percent methanol in the mobile phase higher than what we have listed caused a large
shift in the baseline, which was not acceptable. If the quantitation of CZX is not
necessary or important for the experiment of interest, the assay time can be shortened
to eliminate CZX.
Most published procedures do not list validation parameters such as limit of
detection or recoveries for OH-CZX and CZX which makes it difficult to compare our
method with others. We do feel that our limit of detection and recovery for both
compounds is more than adequate for microsomal studies.

In cases where validation

parameters are listed , ours are equal to or better than existing methods. Use of
phenacetin as the internal standard corrects for intra- and inter-assay variability in the
method .
HPLC procedures involving extraction of OH-CZX and CZX described by
Thummel et al. (1993) used 5 ml of methylene chloride for extraction and have a
quantitation range of 250-5000 ng/ml. While Peter et al. (1990) and Taavitsainen et al.
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(2001) require microsome samples to be extracted 2 times with methylene chloride
before evaporation and injection, with a limit of detection of 90 ng/ml. Lillibridge et al.
(1998) also used methylene chloride and indicates that standard curves were linear over
their respective ranges and interday and intraday coefficients of variation were less than
10%. Chittur and Tracey (1997) used an ether extraction, could quantify samples at
amounts of 10 ng or greater and had a recovery between 40 and 45%. Cummings et al.
(2001) used ethyl acetate and flash freezing in a dry-ice acetone bath . Leclercq et al.
(1998) used a zinc sulfate homogenization procedure followed by filtering of the sample.
Our procedure eliminates the use of time consuming liquid-liquid extractions involving
toxic and expensive organic solvents and does not require the use of dry ice,
homogenizers, nitrogen evaporation or sample filters . It is a rugged procedure with the
column still in use after over 2000 injections and the guard column replaced roughly
every 300 injections. We chose this particular column because of its longevity and
ruggedness as well as its ability to tolerate the sample type used in the assay without
effecting the resolution of the compounds of interest. Even after 2000, injections the
resolution and peak shape are exceptional with very little increase in pressure.
The present study was conducted in order to develop a method to determine
metabolism of CZX in porcine microsome samples from liver. The method has been
applied to xenobiotic effects on porcine microsomes involving CZX in this laboratory. In
conclusion, a simple, quick and sensitive HPLC procedure has been developed for
analysis of OH-CZX and CZX in porcine hepatic microsome samples.
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Chapter 1: Abstract
A simple, quick, and sensitive HPLC analysis of phenacetin and acetaminophen
in porcine hepatic microsome samples is described . Chromatography was performed on
a YMC-Pack OOS-AQ column using a gradient mobile phase consisting of 0.05%
phosphoric acid (pH 3):methanol. UV detection was measured at 254 nm. The
procedure produced a linear curve for the concentration range 10 -1500 ng/ml, and had
a limit of detection of 5 ng/ml for both compounds . This assay produced accurate and
repeatable quantification of acetaminophen and phenacetin.
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Chapter 2: Introduction
The cytochrome P450 monooxygenase enzyme system is important in terms of
its catalytic versatility and for the sheer number of compounds it detoxifies or activates to
reactive intermediates (Guengerich, 1992; Parkinson, 1996). P450 enzymes are located
in virtually all tissues; however, the largest concentration of these enzymes is found in
the liver endoplasmic reticulum (microsomes). These enzymes play a pivotal role in drug
metabolism. They activate xenobiotics including drugs to toxic and/or tumorigenic
metabolites, aid in determining intensity and duration of action of drugs and detoxify
xenobiotics. Therefore, it is essential to establish the activity and regulation of the P450
system for species selected for pharmacological and toxicological studies. In addition ,
impaired drug disposition in food-producing animals may lead to changes in residue
levels of veterinary drugs and other xenobiotics in edible tissues , milk, or eggs. There is
also concern about the increase in development of drug resistant bacterial strains in
food animals. Much of the information known about P450 enzymes comes from studies
that were conducted in rodents. While very little is known about P450 enzymes in
animals used for food, the pig is becoming a viable alternative to traditional non-rodent
species in pharmacological and toxicological testing (Skaanild and Friis, 1999).
However, information on the P450 system for this species is limited.
The hepatic P450 enzymes in microsomes are mainly responsible for phase I
metabolism, which adds or exposes polar functional groups on a lipophilic substrate. In
the investigation of P450 mediated xenobiotic metabolism, individual forms of P450 have
been found to catalyze specific reactions with certain substrates. These activities are
designated as probes for specific P450 enzyme action . To date, at least one marker
activity exists for the majority of human P450 enzymes (Sharer et al. , 1995).
Phenacetin-O-deethylation to acetaminophen (Figure 5-1) is one method used to
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characterize cytochrome P450 enzyme CYP1A2 activity. Several high performance
liquid chromatography (HPLC) methods have been developed to measure
acetaminophen and phenacetin in biological fluids and microsomes (Bormet al., 1983;
Bartoli et al., 1996; McKillop et al., 1998; Lillibridge et al., 1998; Eagling et al., 1998;
Dong et al., 1999; Nakajima et al., 1999; Kobayashi et al. , 1999; Kudo et al., 2000;
Zhang et al. , 2001 ). Many microsome methods involve the use of liquid-liquid
extractions and evaporation (Bormet al. , 1983; McKillop et al., 1998; Lillibridge et al. ,
1998; Eagling et al., 1998; Nakajima et al., 1999; Kobayashi et al., 1999; Zhang et al. ,
2001) while one method (Kudo et al., 2000) uses extraction cartridges. The majority of
the methods also involve the use of human or rat microsomes, but not porcine
microsomes.
We describe an easy and efficient method for analysis of acetaminophen and
phenacetin, which may facilitate characterization of P450 metabolism in the pig.

89
Chapter 3: Materials and Methods
Reagents and Standards
Methanol (HPLC grade), phosphoric acid (reagent grade), magnesium chloride
(enzyme grade), potassium phosphate (enzyme grade), and ethylenediaminetetraacetic
acid (EDTA) (enzyme grade) were purchased from Fisher Scientific (Pittsburgh, PA,
USA). Phenacetin, acetaminophen, glucose 6-phosphate (G-6-P), glucose 6-phosphate
dehydrogenase (G-6-PDH), p-nicotinamide adenine dinucleotide phosphate (NADP) and
trimethoprim (TMP), the internal standard, were purchased from Sigma Chemical
Company (St. Louis, MO, USA).
Stock standard solutions of phenacetin (100, 5 and 1 µg/ml) and acetaminophen
(100, 5, and 1 µg/ml) were prepared in methanol and stored at 4°C. These solutions
were stable for six months. Working standards were prepared fresh daily by dilution of
the stock standards. Stock standard solutions of TMP (50, and 25 µg/ml) were prepared
in methanol and stored at 4°C. These solutions were also stable six months. Phenacetin
is light sensitive and all solution containers were wrapped in aluminum foil.
Apparatus and Chromatographic Conditions
The analytical system consisted of a 626 solvent delivery system, a model 717
WISP autosampler, a 996 scanning UV detector, and a computer equipped with
Millennium software (Waters, Milford, MA, USA). The column was a YMC-Pack ODS
AQ (5 µm, 6 x 150 mm) equipped with a C18 Guard-Pak precolumn insert (Waters,
Milford. MA, USA).
The mobile phase consisted of a mixture of (A) 0.05% phosphoric acid pH 3.0
and (B) methanol. The mixture was pumped as a gradient starting at 74% A and 26% B
and maintained for 4 min . Then over a 5 min period , the mixture was changed to 66% A
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and 34% B and maintained for 9 min . Over the next 4 min period, the system was
returned to initial conditions and ready for the next injection without further equilibration .
The mobile phase was prepared fresh daily using double-distilled , deionized water,
filtered (0.22 µM) and degassed before use. Flow rate was 1.5 ml/min, column
temperature was ambient, and detection was measured at 254 nm .
Sample Treatment
Spiked samples were prepared by the addition of standards (phenacetin,
acetaminophen and TMP) to appropriate amounts of the solutions used in microsomal
preparation to produce a 0.5 ml final volume . Samples were vortex-mixed and a 190 µI
sample was injected onto the liquid chromatograph.
Microsomal samples were prepared using Lake's ( 1987) ultracentrifugation
method. Incubation mixtures contained 0.5 mg of microsomal protein , 100 mM
phosphate buffer at pH 7.4 containing 6 mM magnesium chloride , 1 mM EDTA, and an
NADPH-generating system (1 mM NADP, 10 mM G-6-P and 0.7 U of G-6-PDH) in a total
volume of 0.5 ml. Incubation mixtures contained phenacetin and inhibitors, and the
reactions were initiated by addition of the NADPH-generating system after a 5 min pre
incubation step at 37°C. Reactions were quenched with 0.1 ml of ice cold acetonitrile
after 20 min in a 37°C shaking water bath , and then placed on ice for 1 hour. Samples
were centrifuged at 16,000 g for 15 min. The supernatants were removed and stored at
-80°C until analysis could be performed . Reaction rates were linear with incubation time
under these conditions. Frozen samples were thawed on ice and vortex-mixed before
use . TMP (50 µI of 25 µg/ml) was added to a 0.5 ml microsome sample and vortex
mixed . Those samples containing particulates were centrifuged for 5 min at 16,000 g in
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an Eppendorf centrifuge (Brinkman Instruments, New York, NY, USA). A 190 µI aliquot
of the supernatant was injected onto the liquid chromatograph.
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Chapter 4: Results
A blank chromatogram for a microsomal sample with no drug added is shown in
Figure 5-2 with a large peak at 2.84 min and smaller peaks at 3.62 and 3.88 min. These
peaks are the result of NADPH generating solution used in the microsome sample;
however, they do not interfere with peaks of interest. The x-axis on chromatograms 5-3
and 5-4 start at 4.5 min in order to eliminate the large NADPH peak, and to provide a
better image of the peaks of interest. The chromatogram in Figure 5-3 represents a
porcine liver microsome sample after incubation with 10 µM of phenacetin for 20 min .
Retention times for acetaminophen , TMP and phenacetin were 5.25, 8.08 and 19.48
min . The chromatogram in Figure 5-4 represents a 500 ng/ml standard with retention
times of 5.28, 8.05 and 19.50 min for acetaminophen, TMP and phenacetin,
respectively.
The method used produced a linear curve for the concentration range of 10 1500 ng/ml for phenacetin and acetaminophen , with correlation coefficients ranging from
0.998 to 0.999 for both compounds . Replicate analyses performed on the same day for
microsomal samples spiked with specific concentrations of phenacetin , produced
coefficients of variation (C.V.) of 1.5% for 60 ng/ml, 1.3% for 750 ng/ml and 0.1 % for
1200 ng/ml. The metabolites' C.V. was 6.9% , 2.3% , and 1.0%, respectively, for the same
concentrations (Table 5-1).
Table 5-1. Intra-assay precision for phenacetin and acetaminophen (n = 4)
Concentration
Phenacetin
Coefficient of
Acetaminophen
Coefficient of
Added (ng/ml)
Concentration
variation(%)
concentration
variation(%)
measured (ng/ml)
measured (ng/ml)
mean±SD
mean±SD
6.9
60
62±1
1.5
58±4
2.3
750
720±9
1.3
722±17
1.0
1200
1206±1
0.1
1186±12
SD = Standard deviation
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Figure 5-2. Blank microsome chromatogram with no drug added. Peaks 2.84, 3.62, and
3.88 result from microsomal generating solution .
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Figure 5-3. Chromatogram of a porcine microsomal sample after incubation with 10 µM
of phenacetin . Peaks: acetaminophen; TMP (internal standard); Phen= phenacetin .
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Table 5-2 . Inter-assay precision for phenacetin and acetaminophen (n = 4)
Concentration
Phenacetin
Coefficient of
Acetaminophen
Coefficient of
added (ng/ml)
Concentration
variation(%)
Concentration
variation(%)
measured n /ml
measured n /ml
10
9.9
5.0
9.8
3.2
25
24
3.7
24
4.2
50
51
2.8
49
6.1
100
97
3.1
99
6.1
250
246
3.5
249
3.8
500
467
1.2
498
3.6
800
789
1.0
791
1.6
1000
978
1.0
987
3.3
1500
1481
1.2
1440
1.3

Results for day-to-day variability for microsomal replicates appear in Table 5-2 . Mean
recoveries of phenacetin were 99% , 96% , 103%, 97% , 98% , 94% , 98% , 98% , and 98 %
for 10, 25, 50, 100, 250, 500, 800, 1000, and 1500 ng/ml. Mean recoveries of
acetaminophen were 98%, 96%, 98%, 99%, 100%, 99%, 99% , 99%, and 96% for 10,
25, 50, 100, 250, 500, 800, 1000, and 1500 ng/ml. The detection limit for both
compounds was 5 ng/ml. This represents a peak approximately three times baseline
noise.
Numerous drugs and chemicals used in inhibition studies were tested for
interference with the chromatographic procedure (Table 5-3). Furafylline was found to
co-elute with phenacetin using the present gradient. This was corrected by changing the
gradient. The first 10 min remains the same as the original gradient, however, the
gradient changes from 66% A, 34% B to 76% A, 24% B from 10 min to 18 min . This is
maintained for 8 min , then over 1 min the gradient is returned to the original conditions
(74%A, 26%B).
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Table 5-3 Chemicals tested for assay interference
Chemicals
Quinidine
Furafylline
7 .8-Benzoflavone
Diethyldithiocarbamate
Ketoconazole
Ciprofloxacin
Bufuralol
Lidocaine
ltraconazole
Chlorzoxazone
NADP
Potassium phosphate
Magnesium chloride
Glucose-6-phosphate
Glucose-6-phosphate dehydrogenase
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Chapter 5: Discussion

Enzyme metabolism studies require a method that is simple, quick, accurate,
sensitive and reproducible . Such an HPLC assay, utilizing UV detection, has been
developed to investigate the conversion of phenacetin to acetaminophen by microsomal
fractions of porcine liver. The assay is sensitive, specific and reproducible, with a high
recovery of the metabolite.
Because we did not use an extraction for our samples, the NADPH generating
solution produced a very large peak initially. In order to prevent any interference with
acetaminophen, the mobile phase was initially adjusted to 74% A and 26% B. We did try
to optimize the chromatography in order to reduce the time between TMP and
phenacetin; however, we found that quinidine, which is used in microsomal studies,
would interfere with TMP when the percent methanol in the mobile phase was higher
than 34% . A higher percentage of methanol also caused a large shift in the baseline,
which was not acceptable. However, if the quantitation of phenacetin is not necessary or
important for the experiment, the analysis time can be reduced.
Most of the procedures in the literature do not list validation parameters such as
limit of detection or recoveries for acetaminophen and phenacetin. However, we feel
that our limit of detection and recovery for both compounds are more than adequate for
microsomal studies. In cases where validation parameters are listed, ours are equal to
or better than existing methods. Use of TMP as the internal standard corrects for intra
and inter-assay variability in the method.
HPLC procedures involved in the determination of acetaminophen and
phenacetin by McKillop et al. (1998) used a propanol :ethyl acetate extraction, flash
freezing of the aqueous phase and evaporation, while Zhang et al. (2001) used an ethyl
acetate extraction. Bormet al. (1983) used 10 ml of dichloromethane for 20 min,
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followed by hydrochloric acid and then a back extraction into diethyl ether for 20 min ,
which must be evaporated. Eagling et al. (1998) used a similar procedure with 10 ml
dichloromethane and 10ml ethyl acetate followed by evaporation, with inter- and intra
assay variabilities of 8.7% and 6.5% . Nakajima et al. (1999), Lillibridge et al. (1998) and
Kobayashi et al. (1999) used 2ml of acetonitrile, vortexed for 10 min, then centrifugation
and evaporation of the organic phase with a dri-block or vacuum evaporator. Kudo et al.
(2000) used extraction cartridges in their procedure. Our procedure eliminates the use of
time consuming liquid-liquid extractions involving toxic and expensive organic solvents,
and does not require the use of dry ice, nitrogen, vacuum evaporation or extraction
cartridges . It is a rugged procedure with the column still in use after over 2300 injections,
and the guard column replaced roughly every 300 injections.
This method was developed in order to facilitate microsome studies involving
phenacetin , and has been applied to metabolism studies conducted in porcine
microsomes in this laboratory. In conclusion, a simple, quick and sensitive HPLC
procedure has been developed for analysis of acetaminophen and phenacetin in hepatic
microsome samples.
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PART VI: DETERMINATION OF MONOETHYLGLYCINEXYLIDIDE AND LIDOCAINE
IN PORCINE MICROSOMAL PREPARATIONS
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Chapter 1: Abstract
A simple, accurate, and sensitive HPLC analysis of monoethylglycinexylidide and

lidocaine in porcine microsome samples is described. Chromatography was performed
on a µBondapak C 18 column using an isocratic mobile phase of 0.03M potassium
dihydrogen phosphate:acetonitrile (87:13), pH 5.9. Detection was measured at 205 nm.
The procedure produced linear curves for the concentration range 50-1000 ng/ml with a
limit of detection of 10 ng/ml. Recoveries for both compounds were greater than 90%.
This assay produced accurate and repeatable results.
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Chapter 2: Introduction
Cytochrome P450 enzymes in the liver play a pivotal role in metabolism. They
are important in terms of their catalytic versatility and sheer number of compounds
detoxified or activated to reactive intermediates (Guengerich, 1992; Parkinson, 1996).
P450 enzymes are present in all species examined to date. They are classified into
families , which in turn are divided into subfamilies. The subfamilies in turn consist of
highly related individual forms. The number of enzymes does differ between species
(Parkinson, 1996). Enzyme levels can vary because of environmental as well as genetic
factors. The largest concentration of P450 enzymes is located in the liver endoplasmic
reticulum (microsomes), but they are located in virtually all tissues .
P450 enzymes activate xenobiotics including drugs to toxic and/or tumorigenic
metabolites, detoxify xenobiotics, and aid in determining intensity and duration of action
of drugs. Drug or xenobiotic metabolism is a direct reflection of the multiple enzyme
systems that characterize different animal species and is often the most important single
factor in the regulation of their concentrations. Therefore, it is essential to establish the
activity and regulation of the P450 system for species selected for pharmacological and
toxicological studies. In addition, impaired drug disposition in food-producing animals
may lead to changes in residue levels of veterinary drugs and other xenobiotics in edible
tissues, milk, or eggs. Much of the information known about P450 comes from studies
conducted in rodents. However, the pig is becoming a popular alternative to traditional
non-rodent species in pharmacological and toxicological testing (Skaanild and Friis,
1999). The information on the P450 enzyme system for this species is limited.
P450 enzymes are mainly responsible for phase I metabolism, which adds or
exposes polar functional groups on a lipophilic substrate. In the investigation of P450
enzyme mediated xenobiotic metabolism, individual forms of P450 have been found to
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catalyze specific reactions with certain substrates. Thus these specific activities or
reactions can be utilized as probes for this particular kind of enzyme. To date, at least
one marker activity exists for the majority of human P450 enzymes (Sharer et al., 1995).
The conversion of lidocaine to monoethylglycinexylidide (MEGX) (Figure 6-1) by N
deethylation is one of the methods used to characterize cytochrome P450 enzyme
CYP3A4 activity. Several high performance liquid chromatography (HPLC) methods
have been developed to measure MEGX and lidocaine in biological fluids and
microsomes (Kawai et al. , 1985; lmaoka et al. , 1990; Oshishi et al., 1993; Tanaka et al. ,
1994; Nakamoto et al. , 1997; Leclercq et al., 1997; Kang et al. , 1999; Wang et al., 1999;
Wang et al., 2000). Many microsome methods involve the use of liquid-liquid extractions
and evaporations (Kawai et al. , 1985; lmaoka et al., 1990; Oshishi et al., 1993; Tanaka
et al. , 1994; Leclercq et al., 1997; Wang et al., 1999; Wang et al., 2000). The majority of
methods also involve the use of human or rat microsomes, but not from swine.
This article describes a quick and efficient method for analysis of MEGX and
lidocaine, which may facilitate characterization of P450 enzyme activity in the pig .
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Lidocaine
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Figure 6-1. Structures of lidocaine, MEGX and GX.
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Chapter 3: Materials and Methods
Reagents and Standards
Acetonitrile (HPLC grade), potassium dihydrogen phosphate (reagent grade),
sodium hydroxide (reagent grade), magnesium chloride (enzyme grade), potassium
phosphate (enzyme grade), and EDTA (enzyme grade) were purchased from Fisher
Scientific (Pittsburgh, PA, USA). Lidocaine was purchased from US Pharmacia
(Rockville, MD, USA). MEGX and glycinexylidide (GX) were gifts from Astra laboratories
(Westboro, MA, USA). Trimethoprim (TMP), glucose 6-phosphate (G-6-P), glucose 6phosphate dehydrogenase (G-6-PDH), and ~-nicotinamide adenine dinucleotide
phosphate (NADP) were purchased from Sigma Chemical Company (St. Louis, MO,
USA).
Stock standard solutions of lidocaine (100, 5 and 1 µg/ml were prepared in
methanol , while stock standard solutions of MEGX and GX (100, 5, and 1 µg/ml) were
prepared in water. All solutions were stored at 4°C. Working standards were prepared
fresh daily by dilution of the stock standards. Stock standard solutions of TMP (50 and
25 µg/ml) were prepared in methanol and stored at 4°C.
Apparatus and Chromatography
The analytical system consisted of a 626 solvent delivery system, a model 717
WISP autosampler, a 486 UV detector and a computer equipped with Millennium
software (Waters, Milford, MA, USA). The column was a µBondapak C 18 (10 µm, 3.9 x
300 mm) equipped with a µBondapak C18 Guard-Pak precolumn insert (Waters, Milford .
MA, USA).
The mobile phase consisted of an isocratic mixture of 0.03M potassium
dihydrogen phosphate pH 5.9 (87%) and acetonitrile ( 13% ). It was prepared fresh daily
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using double-distilled deionized water, filtered (0.22 µM) and degassed before use. The
flow rate was 2.0 ml/min. Column temperature was ambient and detection was
measured at 205 nm.
Sample Treatment
Spiked samples were prepared by the addition of appropriate volumes of GX,
MEGX and lidocaine. The internal standard, TMP (25 µI of 25 µg/ml) was added and
appropriate amounts of the solution used in microsomal preparations were added to
produce a 0.5 ml final volume . Samples were vortex-mixed and a 190 µI sample injected
onto the liquid chromatograph .
Previously frozen microsomal samples were prepared using Lake's (1987)
ultracentrifugation method . Incubation mixtures contained 0.5 mg of microsomal
protein , 100 mM phosphate buffer pH 7.4 containing 6 mM magnesium chloride, 1 mM
EDTA, and a NADPH-generating system (1 mM NADP, 10 mM G-6-P and 0.7 U of G-6PDH) in a total volume of 0.5 ml. Incubation mixtures contained lidocaine and inhibitors
and the reactions were initiated by addition of the NADPH-generating system after a 5
min pre-incubation step at 37°C. Reactions were quenched with 0.05 ml of 1 M NaOH
after 20 min in a 37°C shaking water bath and then placed on ice for 1 hour. Reaction
rates were linear with incubation time under these conditions . Samples were centrifuged
at 16,000 g for 15 min ; the supernatant was removed and stored at -80°C until analysis
could be preformed.
Frozen samples were thawed on ice and vortexed before use. TMP (25 µI of 25
µg/ml) was added to a 0.5 ml microsome sample and vortex-mixed . Those samples
containing particulates were centrifuged for 5 min at 16,000 g in an Eppendorf centrifuge
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(Brinkman Instruments, New York, NY, USA). A 190 µI aliquot of the supernatant was
injected onto the liquid chromatograph.
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Chapter 4: Results
A blank chromatogram for a microsomal sample with no drug added is shown in
Figure 6-2 with large peaks at 1.12, 1.50 and 2.39 min , which are the result of the
NADPH generating solution used in the microsome sample. However, none of these
peaks interfere with the peaks of interest (MEGX, TMP, lidocaine). The x-axis on
chromatogram 6-3 starts at 5 min in order to eliminate the large NADPH peaks and
provide a better image of the peaks of interest. The chromatogram in Figure 6-3
represents a porcine liver microsome sample after incubation with 10 µM of lidocaine for
20 min . Retention times for MEGX, TMP and lidocaine were 7.20, 13.25 and 19.70 min .
GX, which is another metabolite of lidocaine, was not detected in any of the sample
chromatograms.
The method used in this study produced a linear curve for the concentration
range of 50 - 1000 ng/ml for lidocaine and its metabolite, with correlation coefficients
ranging from 0.998 to 0.999 for both compounds . Replicate analyses were performed on
the same day for microsomal samples spiked with specific concentrations of 100 and
800 ng/ml MEGX. Coefficients of variation (C.V.) were 6.6% and 5.1%, respectively.
The C.V. for lidocaine was 2.1%, and 7 .9% for the same concentrations. Day-to-day
variability for microsomal replicates appears in Table 6-1.

Table 6-1 . Inter-assay precision for MEGX and lidocaine (n = 4)
Lidocaine
Coefficient of
MEGX
Concentration
Concentration
variation(%)
Concentration
added (ng/ml)
measured n /ml
measured n /ml
52
6.6
46
50
94
6.3
98
100
242
5.3
246
250
470
1.9
477
500
774
5.3
786
800
897
5.0
990
1000

Coefficient of
variation (%)
9.6
4.3
10.2
6.6
3.0
1.0
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Figure 6-2. Blank microsome chromatogram with no drug added. Peaks 1.12, 1.50 and
2,40 result from microsomal generating solution .
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Figure 6-3. Chromatogram of a porcine microsomal sample after incubation with 10 µM
of lidocaine. Peaks: MEGX; TMP (internal standard); LIDO= lidocaine.
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Mean recoveries of MEGX were 93%, 98% , 99%, 95%, 98%, and 99 % for 50, 100, 250,
500, 800 , and 1000 ng/ml. Mean recoveries of lidocaine were 103%, 94%, 98%, 94%,
96%, and 90% for 50, 100, 250, 500, 800, and 1000 ng/ml. The detection limit for both
compounds was 10 ng/ml. This represents a peak approximately three times baseline
noise. No interference from numerous drugs and chemicals used in inhibition studies
was observed with the chromatographic procedure (Table 6-2).

Table 6-2 . Chemicals tested for assay interference.
Chemicals
Quinidine
Furafylline
7.8-Benzoflavone
Diethyldithiocarbamate
Ketoconazole
Ciprofloxacin
Bufuralol
Chlorzoxazone
ltraconazole
Phenacetin
NADP
Potassium phosphate
Magnesium chloride
Glucose-6-phosphate
Glucose-6-phosphate dehydrogenase
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Chapter 5: Discussion
The characterization of enzyme metabolism studies requires a method to be
simple and accurate, sensitive and reproducible . Such an HPLC assay, utilizing UV
detection, has been developed to investigate the N-deethylation conversion of lidocaine
to MEGX by microsomal fractions of porcine liver. The assay is easy, sensitive, specific
and reproducible, with a high recovery of MEGX.
We did not use an extraction for our samples, which resulted in very large peaks
produced by the NADPH generating solution at the front of the chromatogram. We did
optimize the conditions considering this problem and found that an isocratic mixture of
87% phosphate buffer (pH 5.9) and 13% acetonitrile premixed would prevent
interference from the generating solution peaks. If the quantitation of lidocaine is not
important for the experiment the analysis time can be reduced.
Most of the procedures in the literature do not list validation parameters such as
limit of detection or recoveries for MEGX and lidocaine. However, we feel that our limit
of detection and recovery for both compounds are more than adequate for microsomal
studies. In cases where validation parameters are listed , ours are equal to or better
than existing methods. The use of TMP as an internal standard corrects for intra- and
inter-assay variability in the method.
In the determination of MEGX and lidocaine, Wang et al (1999; 2000) used a
methyl tert-butyl ether extraction. lmaoka et al. (1990), Tanaka et al. (1994), Ohishi et
al. (1993), Nakamoto et al. (1997) and Leclercq et al. (1997) used varying amounts of
ethyl acetate which are then evaporated with vacuum or nitrogen. Kawai et al. (1985)
used 10 ml of ethyl acetate followed by back extraction into sulfuric acid and
neutralization with sodium hydroxide, which is evaporated under reduced pressure. Our
procedure eliminates the use of time consuming liquid-liquid extractions involving toxic
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and expensive organic solvents and does not require the use of nitrogen or vacuum
evaporation. The method did include validation of GX and could be used for its analysis.
However, GX was not detected in any of the porcine samples; therefore, its validation
parameters were not included in this manuscript. It is a rugged procedure with the
column still in use after over 1000 injections and the guard column replaced roughly
every 300 injections.
The chromatographic method described , was developed in order to determine
the metabolism of lidocaine in porcine microsome samples . The procedure has been
applied by our group to metabolism studies of lidocaine in porcine microsomes . In
conclusion, a simple, sensitive and useful HPLC procedure has been developed for
analysis of MEGX and lidocaine in microsome samples.
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PART VII: THE EFFECTS OF CIPROFLOXACIN ON PORCINE HEPATIC
CYTOCHROME P450 METABOLISM OF CHLORZOXAZONE

121
Chapter 1: Abstract
Fluoroquinolones are a relatively new class of antimicrobial drugs that are
commonly used . They have the potential to interact with other drugs, and may alter the
metabolism of both. For example fluoroquinolones administered together with
methylxanthines, such as caffeine and theophylline , have resulted in inhibition of
xanthine metabolism by P450 enzymes . Results of prior studies have indicated that
quinolones inhibit P450 activity in companion animals and rodents . However, there is
very little information available concerning the effects that quinolones have on P450
metabolism in food animals. This study was designed to determine what effect
ciprofloxacin has on hepatic microsomal enzyme activity of swine with regard to the
metabolism of chlorzoxazone (CZX), a drug that is used to characterize cytochrome
P4502E1 enzyme activity. Part two of the study was designed to look at the effects of
chemical inhibitors on CZX metabolism in swine in order to learn more about phase I
biotransformation in this species.
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Chapter 2: Introduction
Quinolone antibiotics are a recent addition to the antimicrobial class of drugs,
and , therefore , limited information is available concerning comparative P450 enzyme
activity. Specific P450 isozyme characterization is needed in food animals because of
the food safety concerns of the public for their proper use (Broad et al. , 1995). More
information about the rate and extent of metabolism to both active and inactive
metabolites is needed, in order for these drugs to continue to be used in animals .
Inappropriate dosage reg imens of antibiotics such as quinolones that are used in
an imals intended for food , may indirectly harm the consumer by favoring development of
antibiotic-resistant bacteria. Improper dosing of these antibiotic agents may also result in
inadvertent consumption of drug residues in edible tissues , milk or eggs .
A documented problem with fluoroquinolone use in human medicine is the
interaction that occurs with these antimicrobial agents and other drugs that may alter the
metabolism of both . Fluoroquinolones administered together with methylxanthines, such
as caffeine and theophylline , have resulted in inhibition of xanthine metabolism by P450
enzymes (De Sarro and De Sarro, 2001, Fuhr et al. , 1990, Sano et al. , 1988). Among
the phase I biotransforming enzymes, the cytochrome P450 system ranks first in terms
of catalytic versatility and the sheer number of chemical agents it is capable of
detoxifying, or activating to reactive intermediates (Parkinson , 1996; Guengerich , 1992).
Results of prior studies have indicated that quinolones inhibit P450 activity in companion
animals (Novotny and Shaw, 1991) and rodents (Vancutsem and Babish, 1996).
However, there is very little information concerning the effects that quinolones have on
P450 metabolism in food animals.
There are important species differences in the function and regulation of
cytochrome P450 enzymes, as well as influence by environmental and genetic factors .
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Some of these variations have been attributed, in part, to the presence of different P450
enzymes and their inducibility (Boobis et al., 1990; Smith, 1991; Guengerich , 1992,).
Possible reasons for species differences are: the relative concentrations of different
biotransforming enzymes; the active site of the enzyme differs amongst species; enzyme
activity is catalyzed by different enzymes or isozymes {the enzyme may be in one
species but completely missing in another); differences in the specificity of the isozyme;
and differences in the biotransforming pathways competing for the substrate (Parkinson,
1996; Boobis et al. , 1990 Mellett, 1969). Any one or combination of these reasons can
have a tremendous impact on the way a chemical is metabolized by a particular species.
A drug that is effectively used in one species could be useless in another because it is
not metabolized efficiently. Likewise, a therapeutic dose in one species could prove to
be lethal in another due to differences in metabolism .
The P450 enzyme system is mainly responsible for phase I metabolism, which
adds or exposes polar functional groups on a lipophilic substrate. In the investigation of
P450 mediated xenobiotic metabolism, individual forms of P450 enzymes have been
found to catalyze specific reactions with specific substrates. Thus characterizing these
specific enzyme activities with these substrates allows their use as probes for the P450
enzymes. To date, at least one marker activity exists for the majority of human P450
enzyme forms (Sharer et al. , 1995). This study was designed to determine what effect
ciprofloxacin has on hepatic microsomal enzyme activity of swine, with regard to the
metabolism of chlorzoxazone (CZX). Chlorzoxazone is used to characterize human
cytochrome P4502E1 enzyme activity. As part of this study, the effects of inhibitor
probes on CZX metabolism in swine were examined to learn more about phase I
biotransformation in this species.
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Chapter 3: Materials and Methods
Chemicals and Reagents
Ketoconazole, 7, 8-benzoflavone, quinidine, phenacetin , diethyldithiocarbamic
acid (DOC), chlorzoxazone, glucose-6-phosphate (G6P), ~-nicotinamide adenine
dinucleotide phosphate (NADP), and glucose-6-phosphate dehydrogenase (G6PDH)
were purchased from Sigma Chemical (St. Louis, MO). Other chemicals were obtained
from the following sources: furafylline from Gentest Corp. (Woburn, MA); ciprofloxacin
from US Pharmacia (Rockville, MD); and hydroxychlorzoxazone from Research
Biochemicals Incorporated (St. Louis, MO). All other high analytical grade reagents and
solvents were purchased from Fisher Scientific (Fair Lawn, NJ).
Porcine Liver Microsomes
Four pigs (3 female and 1 castrated male) were used for the study. The pigs
weighed 29 to 38 kg. and were fed standard pig chow. The animals had no known prior
exposure to any drugs. Microsomes were prepared using an ultracentrifugation
technique described by Lake (1987). The washed microsomes were resuspended in 10
mM Tris-acetate buffer (pH 7.4) containing 1 mM EDTA, and 20% sucrose, and were
frozen at -80°C until used. Protein concentrations were determined using a Pierce
reagent kit (Rockford , IL) and P450 content was determined according to the method of
Omura and Sato (1964).
Enzyme Assays
Incubation mixtures contained 0.5 mg of microsomal protein , 100 mM phosphate
buffer at pH 7.4 containing 6 mM magnesium chloride, 1 mM EDTA, and a NADPH
generating system (1 mM NADP, 10 mM G6P and 0.7 U of G6PDH) in a total volume of
0.5 ml. Incubation mixtures contained substrate and inhibitors and the reactions were
initiated by addition of the NAO PH-generating system after a 5 min pre-incubation step
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at 37°C. Furafylline and DOC were pre-incubated for 15 min at 37°C with the generating
solution and microsomes, followed by initiation of reactions by the addition of substrate.
These inhibitors are mechanism-based and require NADPH-dependent complexation
for activation . The substrate stock solutions were prepared in methanol , and the
methanol content did not exceed 1% when added to the incubations. The substrate
concentrations were 10, 100, 250, and 500 µM , while inhibitor concentrations were 1, 10,
and 100 µM. All inhibitors were dissolved in methanol except DOC and ciprofloxacin ,
which were dissolved in water and 0.067M potassium dihydrogen phosphate (pH 3).
Reactions were quenched with 0.1 ml of ice cold acetonitrile after 20 min in a 37°C
shaking water bath, and then placed on ice for 1 hour. Microsome samples were
centrifuged at 16,000 g for 15 min , after which the supernatants were removed and
stored at -80°C until the analyses could be performed .
Enzyme inhibitors were also incubated without substrate in the assays under the
same conditions , to ensure that their presence did not interfere with the quantitation of
the respective metabolites in the assay.
HPLC System
The HPLC system consisted of a 626 pump, a 717 plus autosampler, a 996
scanning UV detector and a computer equipped with Millennium software (Waters,
Milford , MA). The samples were analyzed using a method developed in our laboratory.
Briefly, previously frozen samples were thawed on ice and vortexed . Thirty microliters of
phenacetin (100 µg/ml) was added to a 0.5 ml sample and 190µ1 was injected onto the
liquid chromatograph. Chromatography was conducted for the measurement of
chlorzoxazone 6-hydroxylation on a YMC-Pack 0OS-AQ column (5 µm, 6 x 150 mm)
equipped with a C 18 Guard-Pak precolumn insert (Waters, Milford , MA). The mobile
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phase consisted of a mixture of (A) 0.05% phosphoric acid pH 3.0 and (B) methanol.
The mixture was pumped as a gradient starting at 60% A and 40% B and maintained for
12 min; then over a 2 min period, the mixture was changed to 58% A and 42% B which
was maintained for 5 min. Then over a 3 min period the system was returned to initial
conditions . UV detection was measured at 287 nm. Calibration curves were
constructed using the pure metabolite and phenacetin as the internal standard.
Data Analysis
Determination of apparent Ki values was carried out using Graphpad Prism
(Graphpad Software, Inc., San Diego CA). Formation rates from the experiments with
inhibitors were evaluated by using Dixon plots ([I] vs. 1N).
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Chapter 4: Results
The effect of the specific P450 inhibitors and ciprofloxacin on the metabolism of
CZX can be seen in Figure 7-1 thru 7-8. The catalytic activities of controls (absence of
inhibitor) were considered 100%.
7, 8-Benzoflavone, which is an inhibitor of P4501A2 activity, had no inhibitory
effect on CZX 6-hydroxylase activity (Figure 7-1 ), even at the highest concentration
(1 00µM). In contrast, the 10 and 100 µM 7,8-benzoflavone concentrations caused
activation of the 2E1 mediated activity at lower substrate concentrations. Sim ilar results
were found for quinidine (P4502D6) (Figure 7-2). Both the 10 and 100 µM
concentrations of quinidine increased CZX metabolism at several concentrations. At the
highest concentration of quinidine, there was a small degree of inhibition (<25%) at 100
µM substrate concentration. Ketoconazole (P4503A4) had mixed results as illustrated in
Figure 7-3. The 1 and 10 µM ketoconazole concentrations had very little effect on CZX
metabolism except at the 10 µM concentration , where inhibition was 27% and 35% ,
respectively.

The 100 µM ketoconazole concentration produced some inhibition at all

CZX concentrations with its greatest effect seen at 10 µM (51 %).
Ciprofloxacin had partial inhibitory effects on CZX metabolism (Figure 7-4 ). The
greatest inhibition occurred at the 1 and 10 µM concentrations (44% to 35%) on the 100
- 500 µM CZX concentrations . The 100 µM ciprofloxacin concentration produced
inhibition from 25% to 36% for the 100 - 500 µM range . In contrast, this same
ciprofloxacin concentration caused stimulation of CZX 6-hydroxylation at the 10 µM
level.
The 100 µM concentration of DOC, which is a specific inhibitor of P4502E1 ,
(Figure 7-5) caused 83% , 91 %, 93%, and 87% inhibition in CZX 6-hydroxylase activity
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for the concentrations 10 to 500 µM . The 1 µM DOC concentration produced over a
50% reduction in activity at all the substrate concentrations while the 10 µM
concentration reduced activity by 60% or more. The type of intersection of the
regression lines observed in the Dixon plot (Figure 7-6) is consistent with mixed non
competitive inhibition . The apparent Ki value was 2 µM.
Furafylline (Figure 7-7), a specific mechanism-based inhibitor of P4501A2 ,
caused 56% to 68% inhibition of activity at its lowest concentration (1 µM). Similar results
were obtained with the 10 and 100 µM furafylline concentrations, with suppression of
activity ranging from 53% to 70%. The regression lines in the Dixon plot (Figure 7-8)
are consistent with non-competitive inhibition . The lines are parallel with no intersection ,
so Ki is irrelevant.
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Figure 7-1. Effects of 7,8-benzoflavone on chlorzoxazone 6-hydroxylation.
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Figure 7-2. Effects of quinidine on chlorzoxazone 6-hydroxylation.
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Figure 7-3. Effects of ketoconazole on chlorzoxazone 6-hydroxylation.
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Figure 7-4. Effects of ciprofloxacin on chlorzoxazone 6-hydroxylation.
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Figure 7-5. Effects of DOC on chlorzoxazone 6-hydroxylation.
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Figure 7-7. Effects of furafylline on chlorzoxazone 6-hydroxylation.
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Chapter 5: Discussion
The effects of ciprofloxacin on the metabolic activity of P4502E1 were evaluated
in this study. As part of this process the effects that chemical inhibitors had on CZX
metabolism in porcine liver microsomes were evaluated. Experiments were conducted
using a wide range of concentrations for both substrate and inhibitor to give more
definitive results. It should be pointed out that CZX and the inhibitors are specific for
human P450 enzymes. Therefore, in animals, effective inhibition by the specific inhibitor
probe will occur only if an enzyme homologous to the human enzyme is responsible for
the activity.
7,8-Benzoflavone and quinidine had very little inhibitory effect on CZX 6hydroxylase activity (<13%), and at some concentrations caused activation. These
results are in agreement with studies conducted in human beings (Newton et al., 1995)
and pigs (Diaz and Squires, 2000). Newton et al. (1995) reported that 7,8-benzoflavone
produced a 2-fold increase in CZX metabolism in human microsomes. Diaz and Squires
(2000) found an increase in activity when quinidine and a-naphthoflavone were used as
inhibitors.
The selectivity of ketoconazole as an inhibitor of P4503A4 in human liver
microsomes (Newton et al., 1995) and P4503A12 in canine liver microsomes (Kuroha et
al., 2002) has been indicated. Newton et al. (1995) found that ketoconazole completely
abolished testosterone p-hydroxylase activity (P4503A4 substrate) at concentrations
greater than 5 µM. Kuroha et al. (2002) found that the administration of a therapeutic
dose of ketoconazole may change the pharmacokinetics of other P4503A 12 substrates
in canines. Ketoconazole has also been implicated in the inhibition of the P4502C
mediated family (Back et al., 1988), and is thought to be an inhibitor of a broad spectrum
of P450 isozymes (Ward and Back 1993). The results indicate that ketoconazole
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produces only a slight inhibition at its highest concentration. This reduction in activity
could be due to the fact that ketoconazole inhibits a broad spectrum of P450 enzymes or
it could be due to non-specific inhibition observed at high concentrations of a specific
inhibitor. The other two ketoconazole concentrations produced very little inhibition of
activity, which suggests that the inhibition produced by the larger concentration is non
specific.
Ciprofloxacin produced some inhibition of P4502E1 enzyme activity in porcine
microsomes .

However, in both humans and rodents, quinolones are thought to exert

their effects on the P4501 A family (Vancutsem and Babish, 1996). It has been reported
(Monshouwer et al. 1996) that porcine liver microsomes have P4501A1, 1A2 and 3A4
activities . Sabol et al. (1998) found that CZX hydroxylation could be catalyzed by both
P4501 A 1 and 3A in swine. In another study, the 6-hydroxylation of CZX in porcine liver
microsomes required a two-enzyme model to describe the kinetic data (Court et al. ,
1997). Both high and low affinity activities were discerned indicating that two enzymes
were involved in the metabolism of CZX. Court's et al (1997) study suggests that
P4502E 1 could be involved in CZX metabolism but does not identify the other enzyme
involved . Similar results have also been documented for the oxidative metabolism of
halothane by P4502E1 in humans (Spracklin et al. , 1997). A high affinity/low capacity
isoform and a low affinity/high capacity isoform were found to be involved . The fact that
more than one enzyme seems to be involved in CZX metabolism and if that enzyme
were to belong to P4501A family might explain why ciprofloxacin had some inhibitory
effect on CZX hydroxylation. This may also provide an explanation of why furafylline , a
mechanism-based inhibitor of P4501A2 produced an inhibitory effect on CZX
hydroxylation. All three inhibitor concentrations produced a similar reduction of enzyme
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activity. The type of inhibition furafylline exhibited was non-competitive, indicating that it
binds to the enzyme substrate complex rather than to the free enzyme form.
The specific P4502E1 inhibitor DOC produced the greatest reduction of CZX
hydroxylation activity of all the inhibitors used. The type of inhibition was non
competitive , which is similar to the results reported by Court et al. (1997). The
suppression of activity by DOC observed in these experiments indicates that an enzyme
similar to human P4502E1 could play a role in the CZX 6-hydroxylase activity in swine.
However, other enzymes are probably involved as evidenced by the inhibition produced
by furafylline and ciprofloxacin .
In conclusion , the results of this study suggest that a P450 enzyme in porcine
liver microsomes belonging to the P4502E family is involved in CZX 6-hydroxylation.
However, both ciprofloxacin and furafylline produced inhibitory effects ; therefore , other
enzymes are probably involved, most likely from the P450 1A family. It is clear that
these inhibitors do not exhibit the same selectivity in porcine microsomal studies as
human studies . This may be due to the differential selectivity of the inhibitors or due to
the involvement of completely different P450 enzymes. Therefore , caution should be
used when drugs metabolized by these enzymes are administered concomitantly with
quinolones.
There is a limited amount of data available on hepatic cytochrome P450
enzymes in domestic animals, including substrate and inhibition specificities. With this in
mind , these results should be used as guidelines for future studies. Since multiple
enzymes appear to be involved in the biotransformation of CZX, and relatively minor
differences exist between species in the amino acid sequence of P4502E1 substrate
preference could be drastically effected . New drugs developed for domestic animals
should be tested on the target species since the metabolism may be markedly different
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PART VIII: CIPROFLOXACIN'S EFFECTS ON PORCINE HEPATIC CYTOCHROME
P450 BIOTRANSFORMATION OF BUFURALOL
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Chapter 1: Abstract
Inappropriate dosages of antibiotics used in animals intended for food may
indirectly harm the consumer by favoring development of antibiotic-resistant bacteria.
This has caused public concern about food safety. Fluoroquinolones are a relatively
newer class of antimicrobial drugs used in food animals and other species including
human beings. Work has been done evaluating hepatic P450 enzyme metabolism of
quinolones in several species. However, little has been done to characterize specific
P450 isozymes in food animals. There are indications that quinolones inhibit P450
enzyme activity in companion animals and rats. However, there is very little information
concerning the effects quinolones have on P450 metabolism in food animals. This study
was designed to determine what effect ciprofloxacin has on the metabolism of bufuralol
in porcine hepatic microsomes. Bufuralol is a drug that is used to characterize human
cytochrome P4502O6 enzyme activity. The effects of chemical inhibitors on bufuralol
metabolism in swine were also studied to learn more about phase I biotransformation in
this species.
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Chapter 2: Introduction
Fluoroquinolones were introduced into clinical medicine roughly 14 years ago.
Because the fluoroquinolones are relatively new antimicrobial agents, limited information
is available concerning P450 enzyme metabolic activity in domestic animals. Although
use of quinolones may be limited due to food safety concerns of the public, specific
P450 enzyme characterization is needed for their proper use in food animals (Broad et
al. , 1995). Inappropriate dosage regimens of antibiotics that are used in animals
intended for food , may indirectly harm the consumer by favoring development of
antibiotic-resistant bacteria. Improper dosing of these antibiotic agents may also result in
inadvertent consumption of drug residues in edible tissues , milk or eggs.
A documented problem with fluoroquinolones used in human medicine is the
interaction that occurs with these antimicrobials and other drugs that may alter the
metabolism of both . Fluoroquinolones administered together with methylxanthines, such
as caffeine and theophylline, have resulted in inhibition of xanthine biotransformation by
P450 enzymes (De Sarro and De Sarro, 2001, Fuhr et al. , 1990, Sano et al. , 1988).
Cytochrome P450 constitutes a superfamily of hemoproteins that play a pivotal role in
the metabolism of a wide variety of xenobiotics and endogenous compounds . The
system is responsible for converting a number of pro-drugs to their pharmacologically
active metabolites. They are also responsible for a number of detrimental metabolic
conversions such as rendering certain chemicals mutagenic or carcinogenic, and
producing toxic metabolites (Parkinson , 1996; Guengerich , 1992). Previous studies have
indicated that quinolones inhibit P450 activity in companion animals (Novotny and Shaw,
1991) and rodents (Vancutsem and Babish , 1996). However, there is very little
information concerning the effects that quinolones have on P450 metabolism in food
animals.
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There are important species differences in the function and regulation of
cytochrome P450 enzymes, as well as influence by environmental and genetic factors.
Some of these species variations have been attributed in part, to the presence of
different P450 enzymes and their inducibility (Guengerich, 1992; Smith, 1991; Boobis et
al., 1990). Possible reasons for species differences in cytochrome P450 activity are: the
relative concentrations of different biotransforming enzymes; the active site of the
enzyme differs amongst species; the P450 activity is catalyzed by different enzymes or
isozymes (the enzyme may be in one species but completely missing in another);
differences in the specificity of the isozyme; and differences in the biotransformation
pathways competing for the substrate (Parkinson, 1996; Boobis et al., 1990; Mellett,
1969). Any one or combination of these reasons can have a tremendous impact on the
way a drug or xenobiotic is metabolized by a particular species. A drug that is effectively
used in one species could be useless in another because it is not metabolized efficiently.
Likewise, a therapeutic dose in one species could prove to be lethal in another due to
differences in metabolism.
The P450 enzyme system is mainly responsible for phase I metabolism, which
adds or exposes polar functional groups on a lipophilic substrate. In the investigation of
P450 mediated xenobiotic metabolism, individual forms of P450 enzymes have been
found to catalyze specific reactions with specific substrates. Characterizing these
specific enzyme activities with these substrates allows their use as probes for P450
enzymes. To date, at least one marker activity exists for the majority of human P450
enzymes (Sharer et al., 1995). P4502O6 is an important human isoform and it is
recognized to be involved in the metabolism of over 30 drugs (Jurima-Romet et al.,
2000). P4502O6 is a genetically polymorphic enzyme, and many substrates
predominantly metabolized by it are not well metabolized by other P450 isoforms. An
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animal model for P4502O6 has been sought with little success. Neither rat nor mouse
forms of P4502O are similar to the human enzyme in terms of enzyme characterization
or at the primary sequence level (Jurima-Romet et al. , 2000)
This study was designed to determine what effect ciprofloxacin has on the
metabolism of bufuralol in porcine hepatic microsomes. Bufuralol is used to characterize
human cytochrome P4502O6 enzyme activity, As part of this study, the effects of other
inhibitor probes on bufuralol metabolism in swine were examined to learn more about
phase I biotransformation in this species . Experiments were conducted using a wide
range of concentrations for both substrate and inhibitors to give more conclusive results.
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Chapter 3: Materials and Methods
Chemicals and Reagents
Ketoconazole, 7, 8-benzoflavone, quinidine, chloropropamide ,
diethyldithiocarbamic acid (DOC), glucose-6-phosphate (G6P), p-nicotinamide adenine
dinucleotide phosphate (NADP), and glucose-6-phosphate dehydrogenase (G6PDH)
were purchased from Sigma Chemical (St. Louis , MO). Other chemicals were obtained
from the following sources: furafyll ine, bufuralol and 1'-hydroxybufuralol from Gentest
Corp. (Woburn , MA); and ciprofloxacin from US Pharmacia (Rockville, MD). All other
high analytical grade reagents and solvents were purchased from Fisher Scientific (Fair
Lawn , NJ).
Porcine Liver Microsomes
Four pigs (3 female and 1 castrated male) were used and weighed 29 to 38 kg .
The animals were fed standard pig chow and had no known prior exposure to drugs.
Hepatic microsomes were prepared using an ultracentrifugation technique described by
Lake (1987). The washed microsomes were resuspended in 10 mM Tris-acetate buffer
(pH 7.4) containing 1 mM EDTA, and 20% sucrose, and were then frozen at -80°C until
used . Protein concentrations were determined using a Pierce reagent kit (Rockford , IL),
and P450 content was determined according to the method of Omura and Sato (1964 ).
Enzyme Assays
Incubations contained 0.5 mg of microsomal protein , 100 mM phosphate buffer at
pH 7.4 containing 6 mM magnesium chloride, 1 mM EDTA and a NADPH-generating
system (1 mM NADP, 10 mM G6P and 0.7 U of G6PDH) in a total volume of 0.5 ml.
Incubation mixtures contained substrate and inhibitors, and the reactions were initiated
by the addition of the NADPH-generating system after a 5 min pre-incubation step at
37°C. Furafylline and DOC were preincubated for 15 min at 37°C with the generating
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solution and microsomes, with reactions initiated by the addition of substrate.

These

inhibitors are mechanism-based and requ ire NADPH-dependent complexation for
activation . The substrate stock solutions were prepared in water and were 10, 50, and
100 µM , while inhibitor concentrations were 1, 10, and 100 µM . All inhibitors were
dissolved in methanol except DOC and ciprofloxacin , which were dissolved in water and
0.067M potassium dihydrogen phosphate (pH 3). The methanol was evaporated before
the start of the experiments . Enzyme reactions were quenched with 0.1 ml of ice cold
acetonitrile after 10 min in a 37°C shaking water bath , and then placed on ice for 1 hour.
Microsome samples were centrifuged at 16,000 g for 15 min after which the
supernatants were removed and stored at -80°C until the analyses could be performed .
The specific enzyme inhibitors were also incubated without substrate in the
assays under the same conditions , to ensure that their presence did not interfere with
the quantitation of the respective metabolites.
HPLC System
The HPLC system consisted of a 626 pump, a 717 plus autosampler, a 4 70
fluorescence detector and a computer equipped with Millennium software (Waters,
Milford , MA). The samples were analyzed by a method developed in our laboratory.
Briefly, previously frozen samples were thawed on ice and vortexed . One hundred
microliters of chloropropamide (300 µg/ml) was added to 0.5 ml sample and 125µ1was
injected onto the liquid chromatograph . Chromatography was conducted for the
measurement of bufuralol 1'-hydroxylation on a Resolve C 18 column (5 µm, 3.9 x 150
mm) equipped with a C 18 Guard-Pak precolumn insert (Waters, Milford , MA). The
mobile phase was sodium perchlorate:acetonitrile (48:52) pH 2.45 (adjusted with
perchloric acid) at a flow rate of 1 ml/min . Fluorescence detection occurred at an
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excitation 252 nm and emission 302 nm . All chromatograms were obtained with the
following fluorometric conditions : gain 1OX, attenuation 1, and filter time constant 0.5 s.
Calibration curves were constructed using the pure metabolite 1'-hydroxybufuralol and
chloropropamide as the internal standard.
Data Analysis
Determination of apparent Ki values was carried out using Graphpad Prism
(Graphpad Software, Inc., San Diego CA). Formation rates from the experiments with
inhibitors were evaluated by using Dixon plots ([I] vs . 1N).
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Chapter 4: Results
Specific chemical P450 inhibitors and ciprofloxacin were tested for their effects
on bufuralol 1'-hydroxylation, which are illustrated in Figure 8-1 thru 8-9. The catalytic
activities of controls (absence of inhibitor) were considered 100%.
Furafylline, which is a mechanism-based inhibitor of P4501A2 , had very little
inhibitory effect on bufuralol 1'-hydroxylation (Figure 8-1 ). In fact, furafylline and 7,8benzoflavone, which is another probe for P4501A2 activity, (Figure 8-2) both produced a
stimulatory effect. The greatest activation of hydroxylation activity occurred at the 1O
and 50 µM bufuralol concentrations , and was produced by the 1 and 10 µM furafylline
and the 1 and 100 µM 7,8-benzoflavone concentrations .
Quinidine, the specific P4502O6 inhibitor, had little effect on bufuralol metabolism
(<12%) at any concentration (Figure 8-3). The inhibitor did however, produce an
increase in activity at 10 and 50 µM bufuralol concentrations .
Ciprofloxacin produced mixed results as illustrated in Figure 8-4. The 1 µM
inhibitor had very little effect on bufuralol 1'-hydroxylation except at the 100 µM substrate
concentration (36%). The 10 µM ciprofloxacin concentration produced inhibition from
24% to 37% , while the highest concentration tested (100 µM) inhibited activity from 43%
to 53%. The type of intersection of the regression lines observed in the Dixon plot
(Figure 8-5) is characteristic of a mixed (predominantly competitive) inhibition . The
apparent Ki was 161 µM .
As illustrated in Figure 8-6, DOC, a P4502E1 inhibitor, had some inhibitory
effects at all 3 concentrations used (1 , 10 and 100 µM). The greatest effect was seen
with the 100 µM concentration , which produced a 22% to 53% reduction in bufuralol
metabolism over the substrate concentrations used. The Dixon plot (Figure 8-7) reveals
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that it is a non-competitive type of inhibition. Since the lines are parallel with no
intersection the Ki is irrelevant to this type of inhibitor.
Ketoconazole, a P4503A4 inhibitor, caused some inhibition at all 3
concentrations used (Figure 8-8). The 10 µM concentration produced a range of 8% to
49% inhibition, while the 100 µM caused a 32% to 53% reduction in activity. The Dixon
plot (Figure 8-9) is indicative of a mixed non-competitive type of inhibition with an
apparent Ki of 265 µM .
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Figure 8-8. Effects of ketoconazole on bufuralol 1'-hydroxylation.
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Chapter 5: Discussion
In the present study, porcine liver microsomes were used to evaluate the
possible effects that ciprofloxacin might have on the biotransformation of bufuralol, which
in humans is mediated by P4502D6. As part of the study we also looked at the effects
that specific chemical inhibitors (used in human P450 enzyme studies) had on bufuralol
metabolism in porcine liver microsomes. In animals, effective inhibition by the specific
inhibitor probe will occur only if an enzyme homologous to the human enzyme is
responsible for the activity.
Inhibition by DOC at the two lower concentrations was very weak. Only at the
highest concentration did notable inhibition occur. When enzyme inhibition is observed
at only high inhibitor concentrations, this may represent non-specific inhibition . In a
previous study (Chauret et al., 1997) found that DOC can cause up to 20% or greater
inhibition of other P450 enzyme activities at high concentration ranges. This could
explain why inhibition of activity occurred at the highest DOC concentration . Selectivity
for DOC may also be less in porcine microsomes than seen in human microsomes.
Results indicate that ketoconazole does exhibit some inhibition at both the
medium and high concentrations . Ketoconazole's selectivity as an inhibitor of P4503A4
has been indicated in earlier studies. But, Newton et al. (1995) reported that
ketoconazole inhibited bufuralol 1'-hydroxylation by as much as 80% at 100 µM
concentrations. Ketoconazole has also been implicated in the inhibition of P4502C
reactions and is thought to be an inhibitor of a broad spectrum of P450 enzymes. This is
due to the fact that P4503A4 has a particularly broad substrate specificity and therefore
will play some role in the metabolism of the vast majority of drugs. Thus, even a
relatively selective substrate for 2D6 may have its kinetics contaminated with P4503A4
interferences.
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Ciprofloxacin, which is thought to exert its effects on P4501A2 in humans (Fuhr
et al., 1990), did cause partial inhibition of enzyme activity in porcine microsomes. A
study (Jurima-Romet et al., 2000) conducted in porcine microsomes using
dextromethorphan as the P4502O6 substrate found that both a high affinity and low
affinity component were involved in the metabolism of dextromethorphan . Similar
biphasic kinetics for P4502O6 have been reported in human liver microsomes (Jurima
Romet et al. , 2000). If the metabolism of bufuralol were via a two enzyme kinetic model
this might explain why ciprofloxacin had some inhibitory effect in porcine microsomes.
The other potent inhibitors of P4501A2, 7,8-benzoflavone and furafylline , had no effect
on bufuralol metabolism , which would indicate that the P4501A family is not involved.
However, difference in the levels of individual P450 enzymes, and in the expression of
distinct isoforms may influence the selectivity of inhibitor probes (Eagling et al., 1998).
Also discreet differences in the enzyme active site for substrate/inhibitor combinations
might explain why ciprofloxacin had a greater inhibitory effect than the other two specific
human 1A2 probes.
Quinidine, which is a potent human P4502O6 inhibitor, had no effect on bufuralol
1'-hydroxylation in porcine microsomes. In contrast Jurima-Romet et al. (2000) found
both quinidine and quinine to be potent inhibitors of dextromethorphan , which is a
human P4502O6 substrate, in porcine microsomes. In the same study Jurima-Romet et
al. (2000) also used bufuralol as a P4502O6 substrate, but they used norfluoxetine as a
specific inhibitor not quinidine. Norfluoxetine was a potent inhibitor of bufuralol
metabolism in porcine microsomes in the study. Based on their results Jurima-Romet et
al. (2000) concluded that a P4502O6-like enzyme did metabolize dextromethorphan and
bufuralol. However, our substrate/inhibitor combination of bufuralol and quinidine do not
support this conclusion . Skaanild and Friis (1997 ; 1999) used debrisoquine as a probe
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for P4502D6 activity in conventional pigs and minipigs and reported no activity. In
another study (Monshower et al., 1998), investigators concluded that dextromethorphan
O-demethylation may not be mediated by P4502D in the pig , and that the P4502D
enzyme may be absent from this species. The reason for such discrepancies is
unknown . Possible explanations for the results could be differences in experimental
conditions , the role of various cofactors , the use of different buffers and discreet
differences in the enzyme active site for certain substrate/inhibitor combinations. The
activation and substrate inhibition may be highly dependent on a particular folding
pattern of the protein . Slight changes in the flexible structure of the enzyme may alter the
active site and influence the complex interactions between multiple molecules (Houston
and Kenworthy, 2000).
The interpretation of the inhibition data in animal species, in which little data on
P450 enzymes are available, can be difficult. This is particularly true of 2D6 where
interspecies differences have been reported in terms of inhibition . For example it has
been reported that the rat P4502D1 shares 70% homology with the human P4502D6
and that both species have similar substrate specifiicities. However, quinine is a potent
inhibitor of rat P4502D1 , while its stereoisomer quinidine is not. The converse is true for
human P4502D6. In monkey liver microsomes, quinidine was 40-fold less potent as an
inhibitor of dextromethorphan activity compared to human liver microsomes (Jurima
Romet et al. , 2000).
In summary, the results of this study indicate that there is a P450 enzyme in
porcine liver that is responsible for bufuralol 1'-hydroxylation. Both ciprofloxacin and
ketoconazole produced inhibitory effects; therefore other enzymes are probably
involved. However, since quinidine did not inhibit the activity we cannot say that the
enzyme is P4502D6. It is clear that these inhibitors do not exhibit the same selectivity in
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porcine microsomal studies as human studies. This may be due to the differential
selectivity of the inhibitors or due to the involvement of completely different P450
enzymes. The need for further studies with different substrates and inhibitors at several
concentrations and combinations are necessary to make this determination.
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PART IX: THE EVALUATION OF CIPROFLOXACIN ON PORCINE HEPATIC
CYTOCHROME P450 BIOTRANSFORMATION OF PHENACETIN

171
Chapter 1: Abstract
Fluoroquinolones administered together with methylxanthines, such as caffeine
and theophylline , have resulted in inhibition of the xanthine's metabolism by cytochrome
P450 enzymes in humans. Previous studies have indicated that quinolones inhibit P450
activity in companion animals and rodents . However, there is very little information
available concerning the effects that quinolones have on P450 metabolism in food
animals. There are important species differences in the function and regulation of
cytochrome P450 enzymes, as well as influence by environmental and genetic factors .
Many factors can impact the way a drug is metabolized by a particular species.
Th is study was designed to determine what effect ciprofloxacin has on the metabolism of
phenacetin in porcine hepatic microsomes. Phenacetin is used to characterize human
cytochrome P4501A2 enzyme activity. As part of this assessment of cytochrome
enzyme activity, we looked at the effects that other inhibitor probes had on phenacetin
O-deethylation in porcine liver microsomes.
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Chapter 2: Introduction
Fluoroquinolones are a series of synthetic antibacterial agents that are relatively
new; therefore , limited information is available concerning P450 enzyme activity in
animals. Quinolone use in animals may be limited due to consumer health-related
concerns ; therefore , to use them properly in food animals, specific P450 enzyme
characterization is needed (Broad et al. , 1995). Inappropriate dosage regimens of
antibiotics such as quinolones, that are used in animals intended for food, may indirectly
harm the consumer by favoring development of antibiotic-resistant bacteria . Improper
dosing of these antibiotic agents may also result in inadvertent consumption of drug
residues in edible tissues , milk or eggs.
A documented problem with fluoroquinolone use in human medicine is the
interaction that occurs with these antimicrobials and other drugs that may alter the
metabolism of both. Fluoroquinolones administered together with methylxanthines (such
as caffeine and theophylline) have resulted in inhibition of the xanthine's metabolism by
cytochrome P450 enzymes (De Sarro and De Sarro, 2001, Fuhr et al., 1990, Sano et al. ,
1988). Among the phase I biotransforming enzymes, the cytochrome P450 system
plays a pivotal role in the metabolism of a wide variety of xenobiotics and endogenous
compounds . They also are capable of converting drugs to active metabolites as well as
rendering some chemicals mutagenic or carcinogenic, producing toxic metabolites
(Parkinson, 1996; Guengerich , 1992). Results of previous studies have indicated that
quinolones inhibit P450 activity in companion animals (Novotny and Shaw, 1991) and
rodents (Vancutsem and Babish, 1996). However, there is very little information
available concerning the effects that quinolones have on P450 metabolism in food
animals.
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There are important species differences in the function and regulation of
cytochrome P450 enzymes, as well as influence by environmental and genetic factors.
Some of these variations have been attributed in part, to the presence of different P450
enzymes and their inducibility (Guengerich, 1992; Smith, 1991; Boobis et al., 1990).
Possible reasons for species differences in cytochrome P450 activity are: the relative
concentrations of different biotransforming enzymes; the active site of the enzyme differs
amongst species; the P450 activity is catalyzed by different enzymes or isozymes (the
enzyme may be in one species but completely missing in another); differences in the
specificity of the isozyme; and differences in the biochemical pathways competing for the
substrate (Parkinson , 1996; Boobis et al., 1990; Mellett, 1969). Any one or combination
of these reasons can have a tremendous impact on the way a drug is metabolized by a
particular species. A drug that is effectively used in one species could be useless in
another because it is not metabolized efficiently. Likewise, a therapeutic dose in one
species could prove to be lethal in another due to differences in metabolism.
The P450 enzymes are mainly responsible for phase I metabolism, which
converts drugs and other lipophilic chemicals, low in solubilities, to metabolites that are
more hydrophilic and more readily eliminated. The human P4501A family contains 1A1
and 1A2. Human 1A1 metabolizes carcinogens but is essentially absent from the liver
and is restricted to extrahepatic tissues . P4501A2 participates in the hepatic oxidation of
drugs such as acetaminophen, clozapine and xanthines such as theophylline and
caffeine. P4501A2 represents 10-15% of total P450 content in human liver, although
there is substantial inter-subject variation in expression (Murray, 1999). In the
investigation of P450 mediated xenobiotic metabolism, individual forms of human P450
enzymes have been found to catalyze specific reactions with specific substrates.
Characterizing these specific enzyme activities with these substrates allows their use as
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probes for the P450 enzymes. To date, at least one marker activity exists for the majority
of human P450 enzymes (Sharer et al., 1995). This study was designed to determine
what effect ciprofloxacin has on the metabolism of phenacetin in porcine hepatic
microsomes. Phenacetin is used to characterize human cytochrome P4501 A2 enzyme
activity. As part of this process of examining P450 activity in hepatic microsomes we
looked at the effects that other inhibitor probes had on phenacetin O-deethylation in
porcine liver microsomes.
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Chapter 3: Materials and Methods
Chemicals and Reagents
Ketoconazole , 7, 8-benzoflavone, quinidine, phenacetin , trimethoprim (TMP),
diethyldithiocarbamic acid (DOC), acetaminophen, glucose-6-phosphate (G6P), ~
nicotinamide adenine dinucleotide phosphate (NADP), and glucose-6-phosphate
dehydrogenase (G6PDH) were purchased from Sigma Chemical (St. Louis, MO). Other
chemicals were obtained from the following sources: furafylline from Gentest Corp.
(Woburn , MA) and ciprofloxacin from US Pharmacia (Rockville, MD). All other high
analytical grade reagents and solvents were purchased from Fisher Scientific (Fair
Lawn, NJ).
Porcine Liver Microsomes
Four pigs (3 female and 1 castrated male) were used . The pigs weighed 29 to 38
kg. The animals were fed standard pig chow and had no known prior exposure to any
drugs. Microsomes were prepared using an ultracentrifugation technique described by
Lake (1987). The washed microsomes were resuspended in 10 mM Tris-acetate buffer
(pH 7.4) containing 1 mM EDTA, and 20% sucrose, and were then frozen at -80°C until
used . Protein concentrations were determined using a Pierce reagent kit (Rockford, IL)
and P450 content was determined according to the method of Omura and Sato (1964 ).
Enzyme Assays
Incubations contained 0.5 mg of microsomal protein, 100 mM phosphate buffer at
pH 7.4 containing 6 mM magnesium chloride, 1 mM EDTA, and a NADPH-generating
system (1 mM NADP, 1O mM G6P and 0.7 U of G6PDH) in a total volume of 0.5 ml.
Incubation mixtures contained substrate and inhibitors, and the reactions were initiated
by addition of the NADPH-generating system after a 5 min pre-incubation step at 37°C.
Furafylline and DOC were preincubated for 15 min at 37°C with the generating solution
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and microsomes. The reactions were initiated by addition of phenacetin.

These

inhibitors are mechanism-based and requ ire NADPH-dependent complexation for
activation . The phenacetin stock solutions were prepared in methanol , and the
concentration did not exceed 1% when added to the incubations. The substrate
concentrations were 10, 100, 250, and 500 µM, while inhibitor concentrations were 1, 10,
and 100 µM . All inhibitors were dissolved in methanol except DOC and ciprofloxacin ,
which were dissolved in water and 0.067M potassium dihydrogen phosphate (pH 3). The
methanol was evaporated before the start of the reaction. Enzyme reactions were
quenched with 0.1 ml of ice cold acetonitrile after 20 min in a 37°C shaking water bath ,
and then placed on ice for 1 hour. The microsome samples were centrifuged at 16,000
g for 15 min after which the supernatants were removed and stored at -80°C until
analyses could be performed .
Enzyme inhibitors were also incubated without substrate under the same
conditions , to ensure that their presence did not interfere with the quantitation of the
respective metabolites.
HPLC System
The HPLC system consisted of a 626 pump, a 717 plus autosampler, a 996
scanning UV detector and a computer equipped with Millennium software (Waters,
Milford, MA). The samples were analyzed by a method developed in this laboratory.
Briefly, previously frozen samples were thawed on ice and vortexed . Fifty microliters of
TMP (25 µg/ml) was added to 0.5 ml sample and 190µ1 was injected onto the liquid
chromatograph . Chromatography was conducted for the measurement of phenacetin 0deethylation on a YMC-Pack ODS-AO column (5 µm , 6 x 150 mm) equipped with a C18
Guard-Pak precolumn insert (Waters, Milford , MA). The mobile phase consisted of a
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mixture of (A) 0.05% phosphoric acid (pH 3.0) and (B) methanol. The gradient was
started at 74% A and 26% Band was maintained for 4 min; then over a 5 min period, the
mixture was changed to 66% A and 34% B and was maintained for 9 min ; then over a 4
min period the system was returned to initial conditions. UV detection was measured at
254 nm . Calibration curves were constructed using the pure metabolite and TMP as the
internal standard .
Data Analysis
Determination of apparent Ki values was carried out using Graphpad Prism
(Graphpad Software, Inc., San Diego CA). Formation rates from the experiments with
inhibitors were evaluated by using Dixon plots ([I] vs. 1N).
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Chapter 4: Results
The effects of specific P450 inhibitors and ciprofloxacin on the metabolism of
phenacetin O-deethylation are illustrated in Figure 9-1 thru 9-8. The inhibitor probes
used were 7,8-benzoflavone, furafylline, quinidine, DOC, and ketoconazole. The
catalytic activities of controls (absence of inhibitor) were considered 100%.
Quinidine, the P4502D6 inhibitor, had very little effect on phenacetin O
deethylation (Figure 9-1 ). The 10 and 100 µM concentrations increased phenacetin
metabolism at various substrate concentrations and 7,8-benzoflavone, a potent inhibitor
of 1A2 activity, produced similar results (Figure 9-2). Both the 10 and 100 µM
concentrations produced a stimulatory effect on phenacetin metabolism while the 1 µM
concentration produced inhibition of 35% or less.
Ketoconazole, the P4503A4 inhibitor, produced mixed results as illustrated in
Figure 9-3. The 1 and 10 µM concentrations caused very little inhibitory effect (<20%)
with the exception of the 10 µM inhibitor concentration on the 10 µM phenacetin
concentration (39% ). The inhibition produced by the 100 µM ketoconazole ranged from
30% to 68% over the substrate concentrations used.
Furafylline, a mechanism-based inhibitor, is another probe for P4501A2 that was
used in the study (Figure 9-4 ). The 1 µM concentration produced inhibition that ranged
from 8% to 34% , while the 10 and 100 µM concentrations produced similar inhibitory
results (32% to 41 %).
Ciprofloxacin at the 100 µM concentration produced a 60% inhibition of
phenacetin O-deethylation (Figure 9-5). The 1 and 10 µM concentrations produced very
similar inhibitory results (<50%). The appearance of the Dixon plot (Figure 9-6) for
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ciprofloxacin is characteris tic of non-competitive or mixed inhibition. The apparent Ki was
178 µM.
As illustrated in Figure 9-7 , the 100 µM concentration of DOC produced greater
than 70% inhibition of phenacetin O-deethylation while the 1 and 10 µM concentrat ions
exhibited from 46% to 61 % inhibition. The appearanc e of the Dixon plot (Figure 9-8) is
characteristic of non-compe titive or mixed inhibition. The apparent Ki was 131 µM.
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Figure 9-1 . Effects of quinidine on phenacetin O-deethylation.

500

600

181

140

7, 8-Benzoflavone

120 ·

100

80

e

C:

0

0

60

40

20
-+- 8 1

- - - 810
- . - 8100
0 +-----~----~----~----~---~----~
0

100

200

300

400

500

Phenacetin Concentration
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Figure 9-3. Effects of ketoconazole on phenacetin O-deethylation.
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Chapter 5: Discussion
The specificity of an enzyme inhibitor can be evaluated by studying either the
extent of inhibition (by varying the concentration of the inhibitor) or the kinetics of
inhibition (by varying the concentration of the substrates at several fixed concentrations
of inhibitor) . We chose to do both to give more definitive results.
Several studies using 7-ethoxyresorufin as a probe (Skaanild and Friis, 1999;
Skaanild and Friis, 1997; Monshouwer et al. , 1996) have determined that pigs have
P4501A2 and 1A1 activity. However, to our knowledge none have determined if this is a
one or two enzyme Michaelis-Menten model. In humans and rats the metabolism of
phenacetin involved both a high affinity and low affinity enzyme (Eagling et al. , 1998).
The data from our study indicates that more than one enzyme may be involved in
phenacetin O-deethylation in porcine microsomes.
Quinidine, a potent 206 inhibitor, failed to inhibit the phenacetin O-deethylation.
Therefore, cytochrome P4502O6 does not appear to be involved in phenacetin
metabolism.
Both 7 ,8-benzoflavone and furafylline have been reported to be potent inhibitors
of P4501A2 in human liver microsomes (Newton et al. , 1995), although this activity was
not evident in porcine microsomes. The flavone had very little effect on enzyme activity
while furafylline had a slightly greater effect. In contrast, ciprofloxacin produced a much
greater inhibition of enzyme activity than the two specific P4501A2 inhibitors.
Fluoroquinolones are thought to exert their effects on the P4501A family of enzymes in
humans, rodents and possibly in companion animals (Vancutsem and Babish, 1996).
Differences in the levels of individual P450 isozymes, and in the expression of distinct
isoforms, may influence the selectivity of inhibitor probes (Eagling et al. , 1998). Also ,
relatively minor structural alterations in an inhibitor can have dramatic effects on P450
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specificity, both of which might explain why ciprofloxacin had a greater inhibitory effect
than the other two specific human 1A2 probes.
Ketoconazole produced an inhibitory effect on P450 activity, but only at its
highest concentration. Enzyme inhibition that is observed at high concentrations may
represent nonspecific inhibition (Chauret et al., 1997). Selectivity for ketoconazole may
also be less in porcine microsomes than is seen in human microsomes. Ketoconazole
was found to exhibit a much lesser degree of selectivity in rat microsomes when
compared to those of humans (Eagling et al., 1998). Previous studies reported that
ketoconazole was thought to be an inhibitor of a broad spectrum of P450 enzymes
(Newton et al. , 1995).
DOC produced the greatest inhibitory effect on phenacetin 0-demethylation . It
has been suggested that DOC is a selective inhibitor of P4502E1 in human liver
microsomes (Newton et al. , 1995). However, Chang et al. (1994) found that DOC was a
potent inhibitor of P450 1A1 , 1A2 and 2E1. Eagling et al. (1998) also found that DOC
inhibited both P4501A2 and 2E1 activity in rat microsomes. If the metabolism of
phenacetin were via a two enzyme kinetic model as found in humans and rats , this might
explain why DOC had some inhibitory effect in porcine microsomes. It is also possible
that since the two specific P4501A2 inhibitors had very little effect on phenacetin
metabolism , that this reaction might be mediated by 2E1.
In conclusion, the results of this study indicate that a P450 enzyme in porcine
liver is responsible for phenacetin 0-deethylation. Both ciprofloxacin and DOC produced
inhibitory effects; therefore, multiple enzymes are probably involved. However, since 7,8benzoflavone and furafylline did not inhibit the activity, we cannot say that the enzyme is
P4501A2. It is clear that these inhibitors do not exhibit the same selectivity in porcine
microsomal studies as human studies. This may be due to the differential selectivity of
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the inhibitors or due to the involvement of completely different P450 enzymes. The need
for further studies with different substrates and inhibitors at several concentrations are
necessary to make this determination. Caution must be exercised when extrapolating
the effects of enzyme inhibitors between species and using this information to make
predictions concerning the involvement of P450 enzymes.

191

LITERATURE CITED

192
Boobis A.R. , Sesardic D. , Murray B.P., Edwards R.J ., Singleton A.M ., Rich K.J., Murray
S., Dela Torre R., Segura J. , Pelkonen 0 ., Pasanen M., Kobayashi S., Zhi-Guang T.,
Davies D.S. 1990. Species variation in the response of the cytochrome P-450
dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20 :1139-

11.fil.
Broad T.E., Burkin D.J ., Cambridge L.M., Maher D.W ., Lewis P.E., Ansari H.A., Pearce
P.D., Jones C. 1995. Assignment of five loci from human chromosome 8q onto sheep
chromosome 9. Cytogenetics and Cell Genetics 68:102-106 .
Chang T .K.H., Gonzalez F.J. , Waxman D.J. 1994. Evaluation of triacetyloleandomycin ,
a -naphthoflavone and diethydithiocarbamate as selective chemical probes for
inhibition of human cytochrome P450. Archives of Biochemistry and Biophysics
311 :437-442.
Chauret N. , Gauthier A. , Martin J., Nicoll-Griffith D. 1997. In vitro comparison of
cytochrome P450-mediated metabolic activities in human , dog , cat, and horse. .D.r.ug
Metabolism and Disposition 25:1130-1136.
De Sarro A., De Sarro G . 2001. Adverse reactions to fluoroquinolones . An overview
on mechanistic aspects. Current Medical Chemistry 8:371-384 .
Eagling V.A. , Tjia J.F. , Back D.J. 1998. Differential selectivity of cytochrome P450
inh ibitors against probe substrates in human and rat liver microsomes . British Journal
of Clinical Pharmacology 45:107-114.
Fuhr U., Wolff T ., Harder S., Schymanski P., Staid A.H . 1990. Quinolone inhibition of
cytochrome P-450-dependent caffeine metabolism in human liver microsomes. .Drug
Metabolism and Disposition 18:1005-1010.
Guengerich F.P. 1992. Characterization of human cytochrome P450 enzymes. FASEB
Journal 6:745-748.
Lake B. 1987. Preparation and Characterization of Microsomal Fractions for Studies on
Xenobiotic Metabolism in K. Snell, B. Mullock (Eds .), Biochemical Toxicology A
Practical Approach , IRL Press, Washington DC. pp . 183-215.
Mellett L.B. 1969. Comparative drug metabolism. Progressive Drug Research 13: 136-

1.fil!.
Monshouwer M ., van't Klooster G.A.E., Nijmeijer S.M., Witkamp RF ., van Miert
A.S.J.P .A.M . 1998. Characterization of cytochrome P450 isoenzymes in primary cultures
of pig hepatocytes. Toxicology in Vitro 12:715-723.
Murray M. 1999. Mechanisms and significance of inhibitory drug interaction involving
cytochrome P450 enzymes (review) . International Journal of Molecular Medicine
3:227-238.

193
Newton D.J., Wang R.W., Lu A.Y.H. 1995. Evaluation of Specificities in the in vitro
metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and
Disposition 23:154-158.
Novotny M .J., Shaw D.H. 1991 . Effect of enrofloxacin on digoxin clearance and steady
state serum concentrations in dogs. Canadian Journal of Veterinary Research 55: 113116.
Omura T. , Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes.
Journal of Biological Chemistry 239:2370-2378.
Parkinson A. 1996. Biotransformation of xenobiotics in C.D. Klaassen (ed .). Casarett &
Doull 's Toxicology The Basic Science of Poisons 5th ed. McGraw-Hill, New York. pp.
113-187.
Sano M. , Kawakatsu K., Ohkita C. , Yamamoto I., Takeyama M. , Yamashina H., Goto M.
1988. Effects of enoxacin , ofloxacin and norfloxacin on theophylline disposition in
humans . European Journal of Clinical Pharmacology 35:161-165.
Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. 1995.
Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog,
rhesus monkey and cynomolgus monkey. Drug Metabolism and Disposition 23:1231 1241.
Skaanild M.T. , Friis C. 1997. Characterization of the P450 system in Gottingen
minipigs. Pharmacology & Toxicology 80 :28-33.
Skaanild M.T. , Friis C. 1999. Cytochrome P450 sex differences in minipigs and
conventional pigs. Pharmacology & Toxicology 85:174-180.
Vancutsem P.M. , Babish J.G. 1996. In Vitro and in vivo study of the effects of
enrofloxacin on hepatic cytochrome P-450 . Potential for drug interactions. Veterinary
and Human Toxicology 38:254-259.

194

PART X: THE EFFECTS OF CIPROFLOXACIN ON PORCINE HEPATIC
CYTOCHROME P450 METABOLISM OF LIDOCAINE
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Chapter 1: Abstract
Fluoroquinolones are relatively new antimicrobial agents, with limited information
available concerning P450 enzyme activity. Studies have indicated that quinolones
inhibit P450 activity in companion animals and rats. However, there is very little
information concerning the effects that quinolones have on P450 biotransformation in
food animals. There are important species differences in the function and regulation of
cytochrome P450 enzymes, as well as influence by environmental and genetic factors.
This study was designed to determine what effect ciprofloxacin has on the metabolism of
lidocaine in porcine hepatic microsomes. Furthermore, the inhibitory effects of 7,8benzaflavone, furafylline, quinidine, DOC and ketoconazole on lidocaine N-deethylation
were characterized in porcine liver microsomes.
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Chapter 2: Introduction
Fluoroquinolones were introduced into clinical medicine roughly 15 years ago.
These compounds were regarded as nearly ideal antimicrobial agents because of their
broad spectrum of activity as well as their clinically advantageous pharmacokinetic
properties. Although the use of fluoroquinolones in food animals may be limited due to
consumer health-related concerns, P450 enzyme characterization is required to limit
these concerns and to ensure their proper use (Broad et al. , 1995). However, limited
information is available concerning P450 enzyme activity of quinolones. Inappropriate
dosage regimens of antibiotics that are used in animals intended for food , may indirectly
harm the consumer by favoring development of antibiotic-resistant bacteria . Improper
dosing of the antimicrobial agents may also result in inadvertent consumption of drug
residues in edible tissues , milk or eggs.
A problem encountered with fluoroquinolones that are used in human medicine is
the interaction occurring with these antimicrobials and other drugs that may alter the
metabolism of both. Fluoroquinolones administered together with methylxanthines, such
as caffeine and theophylline, has resulted in inhibition of xanthine metabolism by
cytochrome P450 enzymes (De Sarro and De Sarro, 2001, Fuhr et al., 1990, Sano et al. ,
1988). Detoxification of many drugs occurs via P450 enzymes. The P450 system is also
responsible for converting a number of prodrugs to active metabolites as well as
rendering certain chemicals mutagenic or carcinogenic, producing toxic metabolites
(Parkinson, 1996, Guengerich, 1992). Results of prior studies have indicated that
quinolones inhibit P450 activity in companion animals (Novotny and Shaw, 1991) and
rats (Vancutsem and Babish, 1996). However, there is very little information available
concerning the effects that quinolones have on P450 biotransformation in food animals.
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There are important species differences in the function and regulation of
cytochrome P450 enzymes, as well as influence by environmental and genetic factors.
Some of these variations have been attributed in part, to the presence of different P450
enzymes and their inducibility (Guengerich, 1992; Smith, 1991; Boobis et al., 1990).
Possible reasons for species differences in cytochrome P450 activity are: the relative
concentrations of different biotransforming enzymes ; the active site of the enzyme differs
among species; enzyme activity is catalyzed by different enzymes or isozymes (the
enzyme may be in one species but completely missing in another); differences in the
specificity of the isozyme; and differences in the biochemical pathways competing for the
substrate (Parkinson , 1996; Boobis et al. , 1990; Mellett, 1969). Any one or combination
of these reasons can have a tremendous impact on the way a chemical is metabolized
by a particular species . A drug that is effectively used in one species could be useless
in another because it is not metabolized efficiently. Likewise , a therapeutic dose in one
species could prove to be lethal in another due to differences in metabolism.
P450 enzymes are mainly responsible for phase I metabolism , which transforms
drugs and lipophilic chemicals to metabolites that are more hydrophilic and readily
eliminated. Cytochrome P4503A4 is the major form of P450 expressed in normal adult
human liver microsomes. It plays a vital role in the metabolism of both endogenous
substrates and numerous therapeutic agents. These enzymes are capable of oxidizing a
wide variety of compounds ranging in size from monosubstituted benzenes to
cyclosporin. In the investigation of P450-mediated xenobiotic metabolism , individual
forms of P450 enzymes have been found to catalyze specific reactions with certain
substrates. Characterizing these specific enzyme activities with these substrates allows
their use as probes for the P450 enzyme. To date, at least one marker activity exists for
the majority of human P450 enzyme forms (Sharer et al. , 1995). This study was
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designed to determine what effect ciprofloxacin has on lidocaine metabolism in porcine
hepatic microsomes. Lidocaine is used to characterize human cytochrome P4503A4
enzyme activity. A second phase of the studied involved characterization of the
inhibitory effects of 7 ,8-benzaflavone, furafylline, quinidine, DOC and ketoconazole on
lidocaine N-deethylation in porcine liver microsomes.
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Chapter 3: Materials and Methods
Chemicals and Reagents
Ketoconazole , 7, 8-benzoflavone, quinidine, trimethoprim (TMP)
diethyldithiocarbamic acid (DOC), glucose-6-phosphate (G6P), p-nicotinamide adenine
dinucleotide phosphate (NADP), and glucose-6-phosphate dehydrogenase (G6PDH)
were purchased from Sigma Chemical (St. Louis , MO). Other chemicals were obtained
from the following sources: furafylline from Gentest Corp. (Woburn, MA); lidocaine and
ciprofloxacin from US Pharmacia (Rockville , MD) monoethylglycinexylidide (MEGX) and
glycinexylidide (GX) were gifts from Astra laboratories (Westboro, MA). All other high
analytical grade reagents and solvents were purchased from Fisher Scientific (Fair
Lawn, NJ).
Porcine Liver Microsomes
Four pigs (3 female and 1 castrated male) were used, weighing 29 to 38 kg . The
animals were fed standard pig chow and had no known prior exposure to any drugs .
Microsomes were prepared using an ultracentrifugation technique described by Lake
(1987). The washed microsomes were resuspended in 10 mM Tris-acetate buffer (pH
7.4) containing 1 mM EDTA, and 20% sucrose, and frozen at -80°C until used . Protein
concentrations were determined using a Pierce reagent kit (Rockford, IL) and P450
content was determined according to the method of Omura and Sato ( 1964 ).
Enzyme Assays
Incubations contained 0.5 mg of microsomal protein, 100 mM phosphate buffer at
pH 7.4 containing 6 mM magnesium chloride, 1 mM EDTA, and a NADPH-generating
system (1 mM NADP, 10 mM G6P and 0.7 U of G6PDH) in a total volume of 0.5 ml.
Incubation mixtures contained substrate and inhibitors, and the reactions were initiated
by addition of the NADPH-generating system after a 5 min pre-incubation step at 37°C.
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Furafylline and DOC were preincubated for 15 min at 37°C with the generating solution
and microsomes. The reactions were initiated by the addition of substrate.

These

inhibitors are mechanism-based and require NADPH-dependent complexation for
activation . The substrate stock solutions were prepared in methanol, which did not
exceed 1% when added to the incubations. The substrate concentrations were 10, 100,
250 and 500 µM, while inhibitor concentrations were 1, 10, and 100 µM. All inhibitors
were dissolved in methanol except DOC and ciprofloxacin , which were dissolved in
water and 0.067M potassium dihydrogen phosphate (pH 3). Enzyme reactions were
quenched with 0.05 ml of 1 M NaOH after 20 min in a 37°C shaking water bath, and then
placed on ice for 1 hour. Microsome samples were centrifuged at 16,000 g for 15 min,
after which the supernatants were removed and stored at -80°C until analyses could be
performed .
The enzyme inhibitors were also incubated without substrate under the same
conditions to ensure that their presence in the incubation did not interfere with the
quantitation of the respective metabolites .
HPLC System
The HPLC system consisted of a 626 pump, a 717 plus autosampler, a 486 UV
detector, and a computer equipped with Millennium software (Waters, Milford, MA).
Samples were analyzed by a method developed in this laboratory. Briefly, previously
frozen samples were thawed on ice and vortex-mixed. Twenty-five microliters of
trimethoprim was added to 0.5 ml sample and 190µ1 was injected onto the liquid
chromatograph. Chromatography was conducted for the measurement of lidocaine N
deethylation on a µBondapak C 18 column (10 µm, 3.9 x 300 mm) equipped with a
µBondapak C18 Guard-Pak precolumn insert (Waters, Milford, MA). The mobile phase
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was potassium dihydrogen phosphte:acetonitrile (87:13) pH 5.9 at a flow rate of 2
ml/min. UV detection was measured at 205 nm. Calibration curves were constructed
using the pure metabolites MEGX and GX and trimethoprim as the internal standard .
Data Analysis
Determination of apparent Ki values was carried out using Graphpad Prism
(Graphpad Software, Inc., San Diego CA). Formation rates from the experiments with
inhibitors were evaluated by using Dixon plots ([I] vs . 1N).
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Chapter 4: Results
The effects of the five specific P450 inhibitors and ciprofloxacin on the formation
of MEGX are illustrated in Figure 10-1 thru Figure 10-7. Several of the curves in the
figure are missing the 10 µM point due to the limit of detection for the assay. The
catalytic activities of controls (absence of inhibitor) were considered 100%.
7,8-Benzoflavone is an inhibitor for P450 1A2 and had no inhibitory effect on
lidocaine N-deethylation (Figure 10-1 ). In fact, it caused activation at all the
concentrations evaluated.
The specific inhibitor of P450 2E1, DOC (Figure 10-2) had its greatest effect on
lidocaine metabolism at the 100 and 250 µM substrate concentrations. Inhibition at
these 2 concentrations ranged from 60% to 84%. There was some inhibition at the 500
µM concentration; however, it was less than the other 2 concentrations, with a reduction
in activity ranging from 15% to 45%. The 100 µM DOC produced a stimulatory effect at
the 10 µM lidocaine concentration.
The effect of quinidine, a potent P450 206 inhibitor is demonstrated in Figure 103. The largest decrease in activity occurred at the 100 and 250 µM substrate
concentrations, and was produced by the 10 µM (72% & 66%) and 100 µM (75% & 50%)
inhibitors. All three quinidine concentrations caused an increase in lidocaine metabolism
at the 500 µM lidocaine level.
Furafylline, a mechanism-based inhibitor of P450 1A2, produced between 70%
and 75% (1, 10 & 100 µM) inhibition of activity at the 100 µM lidocaine concentration
(Figure 10-4). Inhibition for the 1, 10, and 100 µM concentrations was 49%, 54%, and
75% at the 250 µM lidocaine level. Very little inhibition occurred (<20%) at the 500 µM
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level with the three concentrations used. The 100 µM furafylline concentration produced
a stimulatory effect at the 10 µM lidocaine concentration .
Figure 10-5 represents the effect that ciprofloxacin had on lidocaine metabolism .
The greatest reduction in activity occurred at the 100 µM and 250 µM substrate
concentrations. The 100 µM ciprofloxacin concentration had the greatest effect at the
lower lidocaine concentration and both the 10 µM and 100 µM ciprofloxacin
concentrations produced an equal decrease in activity at 250 µM. Both the 1 µM and 10
µM ciprofloxacin concentrations caused a slight activation in activity at the 500 µM

substrate concentration .
Ketoconazole (Figure 10-6), a P4503A4 inhibitor, produced 66% and 47% (1
µM), 86% and 83% (10µM) and 92% and 91% inhibition of activity at the 100 and 250

µM substrate concentrations. The 10 and 100 µM ketoconazole concentrations
produced 46% and 83% inhibition of activity at the 500 µM lidocaine concentration. The
intersection of the lines in the Dixon plot (Figure 10-7) is characteristic of a non
competitive type of inhibition. The apparent Ki value was 95 µM.
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Chapter 5: Discussion
In this study we evaluated the effects ciprofloxacin had on the metabolic activity
of P450 3A4. As part of this process we also evaluated the effects that chemical
inhibitors had on lidocaine N-deethylation in porcine liver microsomes. Experiments
were conducted using a wide range of concentrations for both substrate and inhibitor to
give more definitive results . Lidocaine and the five inhibitors are known to be specific for
human P450 enzyme studies. In animals, effective inhibition can be expected if an
enzyme is responsible for the activity and is homologous to the one reported for the
activity of that specific probe.
Cytochrome P450 3A4 activity has been reported in pigs (Monshouwer et al. ,
1996; Skaanild and Friis, 1999) using testosterone as a probe. However to our
knowledge it was not determined if this is a one or two enzyme Michaelis-Menten model.
Studies (Nakajima et al., 2002; Wang et al., 2000) conducted in human liver microsomes
indicated that the metabolism of lidocaine is biphasic, with a high affinity and low affinity
component. The major enzymes involved in lidocaine biotransformation in humans were
P4501A2 and 3A4.
Ketoconazole had the greatest inhibitory effect on lidocaine metabolism
suggesting that 3A4 is involved in its metabolism . The biphasic kinetics might explain
why furafylline , a mechanism-based inhibitor of P4501A2, produced an inhibitory effect
on lidocaine deethylation. Ciprofloxacin also exerts its effects on P4501A2 and this may
provide an explanation of why some reduction in activity occurred when it was used as
an inhibitor.
Quinidine and DDC also produced some inhibition of lidocaine metabolism in
porcine microsomes . Studies (Suzuki et al., 1993; Ohishi et al. , 1993) conducted in rat
liver microsomes indicated that lidocaine metabolism is mediated by an enzyme
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belonging to the P4502D family . Therefore , it is possible that an enzyme from the 2D
family could be involved in lidocaine metabolism in pigs. However, to our knowledge , no
studies using lidocaine as a probe for P4503A4 enzyme activity or specific inhibitors
have been conducted using porcine hepatic microsomes.
7,8- Benzoflavone produced stimulatory effect at all three concentrations used .
Th is is in agreement with a study (Shau et al. , 1994) conducted using human
microsomes . Researchers found that 7,8-benzoflavone served as a substrate for
P4503A4 and increased phenanthrene metabolism. Korzekwa et al. (1998) also found
that 7,8-benzoflavone acts as good substrate for 3A4 in humans .
Most P450 oxidations follow standard Michaelis-Menten kinetic analyses (drug
interactions can be predicted from inhibition studies). However, some P450 reactions
have unusual enzyme kinetics , and most of these identified so far have been associated
with P4503A4 (Korzekwa et al. , 1998). The unusual kinetics fall into four categories :
activation , autoactivation , partial inhibition and substrate inhibition . Atypical enzyme
kinetics can also depend on the substrate and inhibitor employed in the study. Kinetic
studies using hepatic microsomes contain a mixture of several P450 enzymes with
overlapping specificity, and the observed rates of metabolism reflect the effect of
several protein-drug interactions. In some cases, complications can arise due to the
differing impact of several isoforms at different substrate concentrations (Houston and
Kenworthy 2000).
In conclusion, the results of this study indicate that a P450 enzyme in porcine
liver is responsible for lidocaine N-deethylation . Ketoconazole produced the greatest
inhibition of enzyme activity indicating P4503A4 is probably involved. However, both
ciprofloxacin and furafylline produced inhibitory effects, which indicates that the
P4501A2 family is involved. Inhibition was also produced by quinidine and DOC,
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indicating other enzymes are also involved. It is clear that these inhibitors do not exhibit
the same selectivity in porcine microsomal studies as in human studies. This may be
due to the differential selectivity of the inhibitors or it may be due to the involvement of
completely different P450 enzymes. The need for further studies with different substrates
and inhibitors at several concentrations are necessary to make this determination.
There is a limited amount of information available on hepatic cytochrome P450 enzymes
in domestic animals, including substrate and inhibition specificities. Keeping this in
mind, these results should be used as guidelines for future studies.
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The hypothesis of this study was that species-dependen t differences in
pharmacokinetic disposition of fluoroquinolone antibiotics are due to differences in
distribution or activity of cytochrome P450 enzymes. Differences in pharmacokinetic
parameters can indirectly affect development of bacterial resistance to quinolone
antibiotics . The specific aims of the study were to : 1) identify differences in ciprofloxacin
and enrofloxacin disposition by allometric analysis of pharmacokinetic data of different
species , and 2) identify hepatic P450 metabolic pathways in pigs using specific
substrates and enzyme inhibitors.
In order to determine if species differences existed in the disposition of the
fluoroquinolones , allometric relationships were analyzed with regard to body weight, half
life, clearance , and volume of distribution . Previously published data from 20 different
species of an imals, including humans , were studied . Results of the allometric analyses
indicated that there was a similarity between clearance and volume of distribution when
related to body weights for both drugs . Absence of significant relationships for half-life of
both drugs may be the result of variability in the rate or extent of drug biotransformation .
Results of the current analyses indicate that it is possible to scale some pharmacokinetic
variables of both enrofloxacin or ciprofloxacin based on body size of species. Further
experimental allometric studies considering such factors as protein binding and specific
conditions (sex , age, fasted or fed , and breed) of the animals should be conducted ,
which would better characterize the ability to scale across species.
The study of P450 metabolism in hepatic tissue of swine was a two-part process ;
1) to see what effect ciprofloxacin had on the metabolism of four specific substrates that
have been used to characterize human P450 enzyme activities; and 2) to look at the
effects that other specific inhibitor probes had on the metabolism of these four
substrates . In order to conduct these experiments, analytical methods had to be
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developed to quantitate the different substrate biotransformation products that were
produced by porcine microsomes. High performance liquid chromatographic methods
were developed and validated for bufuralol, phenacetin , chlorzoxazone and lidocaine.
This involved the selection of appropriate columns, mobile phases, and sample
treatments. Each protocol was validated with regard to intra-assay and inter-assay
variability, limit of detection and recovery.
Bufuralol, chlorozoxazone, phenacetin and lidocaine are specific substrate
probes that have been used to characterize human cytochrome P450 enzymes (i.e.,
206, 2E1 , 1A2 and 3A4) while quinidine, DOC, furafylline , 7,8-benzoflavone and
ketoconazole are specific inhibitors for these enzymatic reactions . These substrates and
inhibitors were chosen to characterize porcine P450 enzymes as well as determine what
effect ciprofloxacin had on the metabolism of these substrates.
The interpretation of enzyme inhibition data in animal species, in which little data
on P450 enzymes are available, can be difficult. The results obtained indicate that a
P450 enzyme in porcine liver is responsible for phenacetin 0-deethylation , bufuralol 1'
hydroxylation, lidocaine N-deethylation and CZX 6-hydroxylation . The specific enzyme
inhibitors (furafylline, 7,8-benzoflavone and quinidine) that were selected for the
phenacetin and bufuralol studies failed to produce inhibitory effects. However,
ketoconazole and DOC, which are specific inhibitor probes for lidocaine and CZX, did
reduce the metabolism of their respective substrate. The results of the microsomal
studies revealed that for each substrate more than one specific inhibitor probe could
reduce the enzymatic activity, indicating that more than one enzyme is involved in their
metabolism .
Ciprofloxacin exhibited slight inhibitory effects on bufuralol 1'-hydroxlation , CZX
6-hydroxylation and lidocaine N-deethylation . However, ciprofloxacin exerted its greatest
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effect on phenacetin O-deethylation. Fluoroquinolones are thought to exert their effects
on the P4501A enzyme family in humans, rodents and possibly companion animals .
However, this may not be the case in swine since two specific inhibitors of the P4501A
enzyme (furafylline and 7 ,8-benzoflavone) were without effect.
It is clear that the enzyme inhibitors that were chosen for these studies do not
exhibit the same selectivity in porcine microsomes as humans, and that different
microsomal enzymes may be responsible for metabolism of ciprofloxacin in swine. This
may be due to the differential selectivity of the enzyme inhibitors, or due to the
involvement of completely different P450 enzymes. Other explanations for the results
could be differences in experimental conditions , the role of various cofactors, use of
different buffers and discreet differences in the enzyme active site for certain
substrate/inhibitor combinations . The activation and substrate inhibition may be highly
dependent on a particular folding pattern of the protein. Slight changes in the flexible
structure of the enzyme may alter the active site and influence the complex interactions
between multiple molecules (Houston and Kenworthy, 2000).
Some of the results, especially those involving P4503A4, may be due to atypical
enzyme kinetics . Most P450 oxidations follow standard Michaelis-Menten kinetic
analyses (drug interactions can be predicted from inhibition studies) but, atypical
enzyme kinetics can depend on the substrate and inhibitor employed in the study.
Kinetic studies using hepatic microsomes contain a mixture of several P450 enzymes
with overlapping specificity, and the observed rates of metabolism reflect the effect of
several protein-drug interactions. In some cases , complications can arise due to the
differing impact of several isoforms at different substrate concentrations (Houston and
Kenworthy, 2000). Thus , there is a need for further studies with different substrates and
inhibitors at several concentrations in order to determine which specific enzymes are
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involved in the biotransformation process in porcine liver microsomes. Results of these
studies provide a foundation for further definition of fluoroquinolone antibiotic disposition
in swine. Further studies needed are: 1) use of the same substrates with different
inhibitors; 2) use of different substrates with the same inhibitors; and 3) use of different
concentrations of both substrates and inhibitors. In particular, studies should be
conducted for comparative effect on fluoroquinolone disposition in food producing
species with human health concerns .
The study results confirm that variability exists across species with regard to
effect of P450 enzyme inhibitor and substrate utilization , and that caution must be
exercised in extrapolating microsomal P450 enzyme kinetics on specific drug
metabolism. The study results also have important implications for new drugs developed
for domestic animals, which ideally would be tested on the target species since
metabolism could be markedly different among species. Perhaps of greatest
importance, these differences in kinetic handling of drugs like the quinolones have
important implications for the development of resistant bacteria in addition to food
residue concerns.
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